<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>406</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15356154</PubmedId>
            <Abstract>The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is not only responsible for receptor binding and virus fusion, but also a major Ag among the SARS-CoV proteins that induces protective Ab responses. In this study, we showed that the S protein of SARS-CoV is highly immunogenic during infection and immunizations, and contains five linear immunodominant sites (sites I to V) as determined by Pepscan analysis with a set of synthetic peptides overlapping the entire S protein sequence against the convalescent sera from SARS patients and antisera from small animals immunized with inactivated SARS-CoV. Site IV located in the middle region of the S protein (residues 528-635) is a major immunodominant epitope. The synthetic peptide S(603-634), which overlaps the site IV sequence reacted with all the convalescent sera from 42 SARS patient, but none of the 30 serum samples from healthy blood donors, suggesting its potential application as an Ag for developing SARS diagnostics. This study also provides information useful for designing SARS vaccines and understanding the SARS pathogenesis.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>4050-7</ArticlePages>
            <ArticleTitle>Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Yuxian</ForeName>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Yusen</ForeName>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Hao</ForeName>
                </Author>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Baojun</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Jingming</ForeName>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Wanbo</ForeName>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Shibo</ForeName>
                </Author>
            </Authors>
            <Affiliations>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Immunodominant Epitopes;MHV surface projection glycoprotein;Membrane Glycoproteins;Peptide Fragments;Reagent Kits, Diagnostic;Recombinant Proteins;Spike Glycoprotein, Coronavirus;Vaccines, Inactivated;Viral Envelope Proteins;Viral Vaccines;spike glycoprotein, SARS-CoV</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Viral(blood); Computational Biology(methods); Epitope Mapping(methods); Humans; Immunodominant Epitopes(administration &amp; dosage; analysis; immunology); Membrane Glycoproteins(administration &amp; dosage; chemical synthesis; immunology); Mice; Mice, Inbred BALB C; Molecular Sequence Data; Peptide Fragments(administration &amp; dosage; chemical synthesis; immunology); Protein Structure, Tertiary(genetics); Rabbits; Reagent Kits, Diagnostic; Recombinant Proteins(administration &amp; dosage; chemical synthesis; immunology); SARS Virus(genetics; immunology); Severe Acute Respiratory Syndrome(diagnosis; immunology; prevention &amp; control); Spike Glycoprotein, Coronavirus; Vaccines, Inactivated(administration &amp; dosage; chemical synthesis; immunology); Viral Envelope Proteins(administration &amp; dosage; chemical synthesis; immunology); Viral Vaccines(administration &amp; dosage; chemical synthesis; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>173</Volume>
                <Issue>6</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>P1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MFIFLLFLTLTSGSDLD</LinearSequence>
                        <StartingPosition>1</StartingPosition>
                        <EndingPosition>17</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>41504</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>17</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>973</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1-17</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MFIFLLFLTLTSGSDLD</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>17</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>972</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1-17</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MFIFLLFLTLTSGSDLD</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>17</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>974</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1-17</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MFIFLLFLTLTSGSDLD</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>17</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P2</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CTTFDDVQAPNYTQHTSSMRGVYYPDEIFR</LinearSequence>
                        <StartingPosition>19</StartingPosition>
                        <EndingPosition>48</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7217</EpitopeId>
                <ReferenceStartingPosition>19</ReferenceStartingPosition>
                <ReferenceEndingPosition>48</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>978</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>28.6</ResponseFrequency>
                            <AssayComments>This peptide, representing the immunodominant site I, was not recognized by healthy donors.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>19-48</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTTFDDVQAPNYTQHTSSMRGVYYPDEIFR</LinearSequence>
                                        <StartingPosition>19</StartingPosition>
                                        <EndingPosition>48</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P3</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGD</LinearSequence>
                        <StartingPosition>278</StartingPosition>
                        <EndingPosition>312</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7066</EpitopeId>
                <ReferenceStartingPosition>278</ReferenceStartingPosition>
                <ReferenceEndingPosition>312</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1074</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>40</NumberOfSubjectsResponded>
                            <ResponseFrequency>95.2</ResponseFrequency>
                            <AssayComments>This peptide, representing the immunodominant site III, was not recognized by healthy donors.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>278-312</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGD</LinearSequence>
                                        <StartingPosition>278</StartingPosition>
                                        <EndingPosition>312</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P4</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFG</LinearSequence>
                        <StartingPosition>511</StartingPosition>
                        <EndingPosition>552</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>6333</EpitopeId>
                <ReferenceStartingPosition>511</ReferenceStartingPosition>
                <ReferenceEndingPosition>552</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1075</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>40</NumberOfSubjectsResponded>
                            <ResponseFrequency>95.2</ResponseFrequency>
                            <AssayComments>This peptide, which overlaps wiht the immunodominant site IV, was not recognized by healthy donors.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>511-552</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFG</LinearSequence>
                                        <StartingPosition>511</StartingPosition>
                                        <EndingPosition>552</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P5</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GVLTPSSKRFQPFQQFGRDVSDFTDSVRDPK</LinearSequence>
                        <StartingPosition>536</StartingPosition>
                        <EndingPosition>566</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>23053</EpitopeId>
                <ReferenceStartingPosition>536</ReferenceStartingPosition>
                <ReferenceEndingPosition>566</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1076</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>35</NumberOfSubjectsResponded>
                            <ResponseFrequency>83.3</ResponseFrequency>
                            <AssayComments>This peptide, which overlaps wiht the immunodominant site IV, was not recognized by healthy donors.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>536-566</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVLTPSSKRFQPFQQFGRDVSDFTDSVRDPK</LinearSequence>
                                        <StartingPosition>536</StartingPosition>
                                        <EndingPosition>566</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P6</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CTDVSTAIHADQLTPAWRIYSTGNNVFQTQAG</LinearSequence>
                        <StartingPosition>603</StartingPosition>
                        <EndingPosition>634</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7129</EpitopeId>
                <ReferenceStartingPosition>603</ReferenceStartingPosition>
                <ReferenceEndingPosition>634</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1077</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>42</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>This peptide, which overlaps wiht the immunodominant site IV, was not recognized by healthy donors.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>603-634</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTDVSTAIHADQLTPAWRIYSTGNNVFQTQAG</LinearSequence>
                                        <StartingPosition>603</StartingPosition>
                                        <EndingPosition>634</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P7</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TLTSGSDLDRCTTFDDV</LinearSequence>
                        <StartingPosition>9</StartingPosition>
                        <EndingPosition>25</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>65110</EpitopeId>
                <ReferenceStartingPosition>9</ReferenceStartingPosition>
                <ReferenceEndingPosition>25</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1082</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>9-25</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLTSGSDLDRCTTFDDV</LinearSequence>
                                        <StartingPosition>9</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1081</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>9-25</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLTSGSDLDRCTTFDDV</LinearSequence>
                                        <StartingPosition>9</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1080</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>17</NumberOfSubjectsResponded>
                            <ResponseFrequency>40.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>9-25</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLTSGSDLDRCTTFDDV</LinearSequence>
                                        <StartingPosition>9</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P8</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DRCTTFDDVQAPNYTQH</LinearSequence>
                        <StartingPosition>17</StartingPosition>
                        <EndingPosition>33</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>9956</EpitopeId>
                <ReferenceStartingPosition>17</ReferenceStartingPosition>
                <ReferenceEndingPosition>33</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1085</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>17-33</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DRCTTFDDVQAPNYTQH</LinearSequence>
                                        <StartingPosition>17</StartingPosition>
                                        <EndingPosition>33</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1083</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>27</NumberOfSubjectsResponded>
                            <ResponseFrequency>64.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>17-33</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DRCTTFDDVQAPNYTQH</LinearSequence>
                                        <StartingPosition>17</StartingPosition>
                                        <EndingPosition>33</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1084</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>17-33</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DRCTTFDDVQAPNYTQH</LinearSequence>
                                        <StartingPosition>17</StartingPosition>
                                        <EndingPosition>33</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P9</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VQAPNYTQHTSSMRGVY</LinearSequence>
                        <StartingPosition>25</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>70527</EpitopeId>
                <ReferenceStartingPosition>25</ReferenceStartingPosition>
                <ReferenceEndingPosition>41</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1086</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>24</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>25-41</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VQAPNYTQHTSSMRGVY</LinearSequence>
                                        <StartingPosition>25</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1087</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>25-41</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VQAPNYTQHTSSMRGVY</LinearSequence>
                                        <StartingPosition>25</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1088</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>25-41</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VQAPNYTQHTSSMRGVY</LinearSequence>
                                        <StartingPosition>25</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P10</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HTSSMRGVYYPDEIFRS</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>49</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>24978</EpitopeId>
                <ReferenceStartingPosition>33</ReferenceStartingPosition>
                <ReferenceEndingPosition>49</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1089</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>25</NumberOfSubjectsResponded>
                            <ResponseFrequency>59.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>33-49</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTSSMRGVYYPDEIFRS</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>49</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1091</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>33-49</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTSSMRGVYYPDEIFRS</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>49</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1090</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>33-49</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTSSMRGVYYPDEIFRS</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>49</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P11</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VYYPDEIFRSDTLYLTQD</LinearSequence>
                        <StartingPosition>40</StartingPosition>
                        <EndingPosition>57</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>72205</EpitopeId>
                <ReferenceStartingPosition>40</ReferenceStartingPosition>
                <ReferenceEndingPosition>57</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1093</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>40-57</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VYYPDEIFRSDTLYLTQD</LinearSequence>
                                        <StartingPosition>40</StartingPosition>
                                        <EndingPosition>57</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1092</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>21</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>40-57</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VYYPDEIFRSDTLYLTQD</LinearSequence>
                                        <StartingPosition>40</StartingPosition>
                                        <EndingPosition>57</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1094</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>40-57</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VYYPDEIFRSDTLYLTQD</LinearSequence>
                                        <StartingPosition>40</StartingPosition>
                                        <EndingPosition>57</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P12</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FRSDTLYLTQDLFLPFY</LinearSequence>
                        <StartingPosition>47</StartingPosition>
                        <EndingPosition>63</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>17644</EpitopeId>
                <ReferenceStartingPosition>47</ReferenceStartingPosition>
                <ReferenceEndingPosition>63</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1097</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>47-63</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FRSDTLYLTQDLFLPFY</LinearSequence>
                                        <StartingPosition>47</StartingPosition>
                                        <EndingPosition>63</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1098</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>47-63</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FRSDTLYLTQDLFLPFY</LinearSequence>
                                        <StartingPosition>47</StartingPosition>
                                        <EndingPosition>63</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1096</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>18</NumberOfSubjectsResponded>
                            <ResponseFrequency>42.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>47-63</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FRSDTLYLTQDLFLPFY</LinearSequence>
                                        <StartingPosition>47</StartingPosition>
                                        <EndingPosition>63</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P13</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TQDLFLPFYSNVTGFHT</LinearSequence>
                        <StartingPosition>55</StartingPosition>
                        <EndingPosition>71</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>65832</EpitopeId>
                <ReferenceStartingPosition>55</ReferenceStartingPosition>
                <ReferenceEndingPosition>71</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1099</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>55-71</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQDLFLPFYSNVTGFHT</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>71</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1100</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>55-71</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQDLFLPFYSNVTGFHT</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>71</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1101</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>55-71</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQDLFLPFYSNVTGFHT</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>71</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P14</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YSNVTGFHT</LinearSequence>
                        <StartingPosition>63</StartingPosition>
                        <EndingPosition>71</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>75843</EpitopeId>
                <ReferenceStartingPosition>63</ReferenceStartingPosition>
                <ReferenceEndingPosition>71</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1102</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>63-71</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSNVTGFHT</LinearSequence>
                                        <StartingPosition>63</StartingPosition>
                                        <EndingPosition>71</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1103</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>63-71</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSNVTGFHT</LinearSequence>
                                        <StartingPosition>63</StartingPosition>
                                        <EndingPosition>71</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1104</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>63-71</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSNVTGFHT</LinearSequence>
                                        <StartingPosition>63</StartingPosition>
                                        <EndingPosition>71</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P15</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HTINHTFGNPVIPFKDG</LinearSequence>
                        <StartingPosition>70</StartingPosition>
                        <EndingPosition>86</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>24923</EpitopeId>
                <ReferenceStartingPosition>70</ReferenceStartingPosition>
                <ReferenceEndingPosition>86</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1106</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>70-86</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTINHTFGNPVIPFKDG</LinearSequence>
                                        <StartingPosition>70</StartingPosition>
                                        <EndingPosition>86</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1105</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>7.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>70-86</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTINHTFGNPVIPFKDG</LinearSequence>
                                        <StartingPosition>70</StartingPosition>
                                        <EndingPosition>86</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1107</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>70-86</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HTINHTFGNPVIPFKDG</LinearSequence>
                                        <StartingPosition>70</StartingPosition>
                                        <EndingPosition>86</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P16</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NPVIPFKDGIYFAATEK</LinearSequence>
                        <StartingPosition>78</StartingPosition>
                        <EndingPosition>94</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>45506</EpitopeId>
                <ReferenceStartingPosition>78</ReferenceStartingPosition>
                <ReferenceEndingPosition>94</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1109</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>78-94</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NPVIPFKDGIYFAATEK</LinearSequence>
                                        <StartingPosition>78</StartingPosition>
                                        <EndingPosition>94</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1110</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>78-94</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NPVIPFKDGIYFAATEK</LinearSequence>
                                        <StartingPosition>78</StartingPosition>
                                        <EndingPosition>94</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1108</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>78-94</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NPVIPFKDGIYFAATEK</LinearSequence>
                                        <StartingPosition>78</StartingPosition>
                                        <EndingPosition>94</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P17</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DGIYFAATEKSNVVRGW</LinearSequence>
                        <StartingPosition>85</StartingPosition>
                        <EndingPosition>101</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>8413</EpitopeId>
                <ReferenceStartingPosition>85</ReferenceStartingPosition>
                <ReferenceEndingPosition>101</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1113</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>85-101</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DGIYFAATEKSNVVRGW</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>101</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1111</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>4.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>85-101</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DGIYFAATEKSNVVRGW</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>101</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1112</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>85-101</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DGIYFAATEKSNVVRGW</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>101</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P18</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TEKSNVVRGWVFGSTMN</LinearSequence>
                        <StartingPosition>92</StartingPosition>
                        <EndingPosition>108</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>63427</EpitopeId>
                <ReferenceStartingPosition>92</ReferenceStartingPosition>
                <ReferenceEndingPosition>108</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1114</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>92-108</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TEKSNVVRGWVFGSTMN</LinearSequence>
                                        <StartingPosition>92</StartingPosition>
                                        <EndingPosition>108</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1116</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>92-108</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TEKSNVVRGWVFGSTMN</LinearSequence>
                                        <StartingPosition>92</StartingPosition>
                                        <EndingPosition>108</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1115</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>92-108</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TEKSNVVRGWVFGSTMN</LinearSequence>
                                        <StartingPosition>92</StartingPosition>
                                        <EndingPosition>108</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P19</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GWVFGSTMNNKSQSVII</LinearSequence>
                        <StartingPosition>100</StartingPosition>
                        <EndingPosition>116</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>23296</EpitopeId>
                <ReferenceStartingPosition>100</ReferenceStartingPosition>
                <ReferenceEndingPosition>116</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1119</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>100-116</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GWVFGSTMNNKSQSVII</LinearSequence>
                                        <StartingPosition>100</StartingPosition>
                                        <EndingPosition>116</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1117</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>100-116</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GWVFGSTMNNKSQSVII</LinearSequence>
                                        <StartingPosition>100</StartingPosition>
                                        <EndingPosition>116</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1118</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>100-116</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GWVFGSTMNNKSQSVII</LinearSequence>
                                        <StartingPosition>100</StartingPosition>
                                        <EndingPosition>116</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P20</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NNKSQSVIIINNSTNVV</LinearSequence>
                        <StartingPosition>108</StartingPosition>
                        <EndingPosition>124</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>45151</EpitopeId>
                <ReferenceStartingPosition>108</ReferenceStartingPosition>
                <ReferenceEndingPosition>124</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1120</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>108-124</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NNKSQSVIIINNSTNVV</LinearSequence>
                                        <StartingPosition>108</StartingPosition>
                                        <EndingPosition>124</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1122</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>108-124</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NNKSQSVIIINNSTNVV</LinearSequence>
                                        <StartingPosition>108</StartingPosition>
                                        <EndingPosition>124</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1121</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>108-124</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NNKSQSVIIINNSTNVV</LinearSequence>
                                        <StartingPosition>108</StartingPosition>
                                        <EndingPosition>124</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P21</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IINNSTNVVIRACNFEL</LinearSequence>
                        <StartingPosition>116</StartingPosition>
                        <EndingPosition>132</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>26610</EpitopeId>
                <ReferenceStartingPosition>116</ReferenceStartingPosition>
                <ReferenceEndingPosition>132</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1125</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>116-132</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IINNSTNVVIRACNFEL</LinearSequence>
                                        <StartingPosition>116</StartingPosition>
                                        <EndingPosition>132</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1123</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>116-132</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IINNSTNVVIRACNFEL</LinearSequence>
                                        <StartingPosition>116</StartingPosition>
                                        <EndingPosition>132</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1124</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>116-132</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IINNSTNVVIRACNFEL</LinearSequence>
                                        <StartingPosition>116</StartingPosition>
                                        <EndingPosition>132</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P22</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TNVVIRACNFELCDNPF</LinearSequence>
                        <StartingPosition>121</StartingPosition>
                        <EndingPosition>137</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>65479</EpitopeId>
                <ReferenceStartingPosition>121</ReferenceStartingPosition>
                <ReferenceEndingPosition>137</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1128</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>121-137</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TNVVIRACNFELCDNPF</LinearSequence>
                                        <StartingPosition>121</StartingPosition>
                                        <EndingPosition>137</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1127</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>121-137</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TNVVIRACNFELCDNPF</LinearSequence>
                                        <StartingPosition>121</StartingPosition>
                                        <EndingPosition>137</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1126</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>121-137</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TNVVIRACNFELCDNPF</LinearSequence>
                                        <StartingPosition>121</StartingPosition>
                                        <EndingPosition>137</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P23</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NFELCDNPFFAVSKPMG</LinearSequence>
                        <StartingPosition>129</StartingPosition>
                        <EndingPosition>145</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43825</EpitopeId>
                <ReferenceStartingPosition>129</ReferenceStartingPosition>
                <ReferenceEndingPosition>145</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1130</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>129-145</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFELCDNPFFAVSKPMG</LinearSequence>
                                        <StartingPosition>129</StartingPosition>
                                        <EndingPosition>145</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1131</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>129-145</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFELCDNPFFAVSKPMG</LinearSequence>
                                        <StartingPosition>129</StartingPosition>
                                        <EndingPosition>145</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1129</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>129-145</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFELCDNPFFAVSKPMG</LinearSequence>
                                        <StartingPosition>129</StartingPosition>
                                        <EndingPosition>145</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P24</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FFAVSKPMGTQTHTMIF</LinearSequence>
                        <StartingPosition>137</StartingPosition>
                        <EndingPosition>153</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>15783</EpitopeId>
                <ReferenceStartingPosition>137</ReferenceStartingPosition>
                <ReferenceEndingPosition>153</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1134</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>137-153</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FFAVSKPMGTQTHTMIF</LinearSequence>
                                        <StartingPosition>137</StartingPosition>
                                        <EndingPosition>153</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1132</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>137-153</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FFAVSKPMGTQTHTMIF</LinearSequence>
                                        <StartingPosition>137</StartingPosition>
                                        <EndingPosition>153</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1133</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>137-153</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FFAVSKPMGTQTHTMIF</LinearSequence>
                                        <StartingPosition>137</StartingPosition>
                                        <EndingPosition>153</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P25</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PMGTQTHTMIFDNAFNC</LinearSequence>
                        <StartingPosition>143</StartingPosition>
                        <EndingPosition>159</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>48554</EpitopeId>
                <ReferenceStartingPosition>143</ReferenceStartingPosition>
                <ReferenceEndingPosition>159</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1135</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>7.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>143-159</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PMGTQTHTMIFDNAFNC</LinearSequence>
                                        <StartingPosition>143</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1136</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>143-159</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PMGTQTHTMIFDNAFNC</LinearSequence>
                                        <StartingPosition>143</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1137</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>143-159</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PMGTQTHTMIFDNAFNC</LinearSequence>
                                        <StartingPosition>143</StartingPosition>
                                        <EndingPosition>159</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P26</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>THTMIFDNAFNCTFEYI</LinearSequence>
                        <StartingPosition>148</StartingPosition>
                        <EndingPosition>164</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>64085</EpitopeId>
                <ReferenceStartingPosition>148</ReferenceStartingPosition>
                <ReferenceEndingPosition>164</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1138</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>148-164</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>THTMIFDNAFNCTFEYI</LinearSequence>
                                        <StartingPosition>148</StartingPosition>
                                        <EndingPosition>164</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1139</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>148-164</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>THTMIFDNAFNCTFEYI</LinearSequence>
                                        <StartingPosition>148</StartingPosition>
                                        <EndingPosition>164</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1140</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>148-164</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>THTMIFDNAFNCTFEYI</LinearSequence>
                                        <StartingPosition>148</StartingPosition>
                                        <EndingPosition>164</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P27</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NAFNCTFEYISDAFSLD</LinearSequence>
                        <StartingPosition>155</StartingPosition>
                        <EndingPosition>171</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43145</EpitopeId>
                <ReferenceStartingPosition>155</ReferenceStartingPosition>
                <ReferenceEndingPosition>171</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1143</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>155-171</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAFNCTFEYISDAFSLD</LinearSequence>
                                        <StartingPosition>155</StartingPosition>
                                        <EndingPosition>171</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1142</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>155-171</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAFNCTFEYISDAFSLD</LinearSequence>
                                        <StartingPosition>155</StartingPosition>
                                        <EndingPosition>171</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1141</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>23.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>155-171</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAFNCTFEYISDAFSLD</LinearSequence>
                                        <StartingPosition>155</StartingPosition>
                                        <EndingPosition>171</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P28</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YISDAFSLDVSEKSGNF</LinearSequence>
                        <StartingPosition>163</StartingPosition>
                        <EndingPosition>179</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>74367</EpitopeId>
                <ReferenceStartingPosition>163</ReferenceStartingPosition>
                <ReferenceEndingPosition>179</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1145</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>163-179</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YISDAFSLDVSEKSGNF</LinearSequence>
                                        <StartingPosition>163</StartingPosition>
                                        <EndingPosition>179</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1144</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>163-179</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YISDAFSLDVSEKSGNF</LinearSequence>
                                        <StartingPosition>163</StartingPosition>
                                        <EndingPosition>179</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1146</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>163-179</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YISDAFSLDVSEKSGNF</LinearSequence>
                                        <StartingPosition>163</StartingPosition>
                                        <EndingPosition>179</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P29</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DVSEKSGNFKHLREFVF</LinearSequence>
                        <StartingPosition>171</StartingPosition>
                        <EndingPosition>187</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>10721</EpitopeId>
                <ReferenceStartingPosition>171</ReferenceStartingPosition>
                <ReferenceEndingPosition>187</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1148</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>171-187</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DVSEKSGNFKHLREFVF</LinearSequence>
                                        <StartingPosition>171</StartingPosition>
                                        <EndingPosition>187</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1147</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>18</NumberOfSubjectsResponded>
                            <ResponseFrequency>42.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>171-187</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DVSEKSGNFKHLREFVF</LinearSequence>
                                        <StartingPosition>171</StartingPosition>
                                        <EndingPosition>187</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1149</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>171-187</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DVSEKSGNFKHLREFVF</LinearSequence>
                                        <StartingPosition>171</StartingPosition>
                                        <EndingPosition>187</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P30</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FKHLREFVFKNKDGFLY</LinearSequence>
                        <StartingPosition>179</StartingPosition>
                        <EndingPosition>195</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>16376</EpitopeId>
                <ReferenceStartingPosition>171</ReferenceStartingPosition>
                <ReferenceEndingPosition>195</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1152</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>179-195</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FKHLREFVFKNKDGFLY</LinearSequence>
                                        <StartingPosition>179</StartingPosition>
                                        <EndingPosition>195</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1151</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>179-195</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FKHLREFVFKNKDGFLY</LinearSequence>
                                        <StartingPosition>179</StartingPosition>
                                        <EndingPosition>195</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1150</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>21</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>179-195</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FKHLREFVFKNKDGFLY</LinearSequence>
                                        <StartingPosition>179</StartingPosition>
                                        <EndingPosition>195</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P31</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FKNKDGFLYVYKGYQPI</LinearSequence>
                        <StartingPosition>187</StartingPosition>
                        <EndingPosition>203</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>16417</EpitopeId>
                <ReferenceStartingPosition>187</ReferenceStartingPosition>
                <ReferenceEndingPosition>203</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1154</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>187-203</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FKNKDGFLYVYKGYQPI</LinearSequence>
                                        <StartingPosition>187</StartingPosition>
                                        <EndingPosition>203</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1155</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>187-203</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FKNKDGFLYVYKGYQPI</LinearSequence>
                                        <StartingPosition>187</StartingPosition>
                                        <EndingPosition>203</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1153</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>23</NumberOfSubjectsResponded>
                            <ResponseFrequency>54.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>187-203</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FKNKDGFLYVYKGYQPI</LinearSequence>
                                        <StartingPosition>187</StartingPosition>
                                        <EndingPosition>203</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P32</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YVYKGYQPIDVVRDLPS</LinearSequence>
                        <StartingPosition>195</StartingPosition>
                        <EndingPosition>211</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>76446</EpitopeId>
                <ReferenceStartingPosition>195</ReferenceStartingPosition>
                <ReferenceEndingPosition>211</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1158</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>195-211</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YVYKGYQPIDVVRDLPS</LinearSequence>
                                        <StartingPosition>195</StartingPosition>
                                        <EndingPosition>211</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1156</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>16</NumberOfSubjectsResponded>
                            <ResponseFrequency>38.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>195-211</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YVYKGYQPIDVVRDLPS</LinearSequence>
                                        <StartingPosition>195</StartingPosition>
                                        <EndingPosition>211</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1157</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>195-211</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YVYKGYQPIDVVRDLPS</LinearSequence>
                                        <StartingPosition>195</StartingPosition>
                                        <EndingPosition>211</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P33</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YQPIDVVRDLPSGFNTL</LinearSequence>
                        <StartingPosition>200</StartingPosition>
                        <EndingPosition>216</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>75528</EpitopeId>
                <ReferenceStartingPosition>200</ReferenceStartingPosition>
                <ReferenceEndingPosition>216</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1161</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>200-216</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YQPIDVVRDLPSGFNTL</LinearSequence>
                                        <StartingPosition>200</StartingPosition>
                                        <EndingPosition>216</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1160</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>200-216</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YQPIDVVRDLPSGFNTL</LinearSequence>
                                        <StartingPosition>200</StartingPosition>
                                        <EndingPosition>216</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1159</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>15</NumberOfSubjectsResponded>
                            <ResponseFrequency>35.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>200-216</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YQPIDVVRDLPSGFNTL</LinearSequence>
                                        <StartingPosition>200</StartingPosition>
                                        <EndingPosition>216</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P34</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DLPSGFNTLKPIFKLPL</LinearSequence>
                        <StartingPosition>208</StartingPosition>
                        <EndingPosition>224</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>9242</EpitopeId>
                <ReferenceStartingPosition>208</ReferenceStartingPosition>
                <ReferenceEndingPosition>224</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1162</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>16</NumberOfSubjectsResponded>
                            <ResponseFrequency>38.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>208-224</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLPSGFNTLKPIFKLPL</LinearSequence>
                                        <StartingPosition>208</StartingPosition>
                                        <EndingPosition>224</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1164</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>208-224</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLPSGFNTLKPIFKLPL</LinearSequence>
                                        <StartingPosition>208</StartingPosition>
                                        <EndingPosition>224</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1163</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>208-224</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLPSGFNTLKPIFKLPL</LinearSequence>
                                        <StartingPosition>208</StartingPosition>
                                        <EndingPosition>224</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P35</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LKPIFKLPLGINITNFR</LinearSequence>
                        <StartingPosition>216</StartingPosition>
                        <EndingPosition>232</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>36991</EpitopeId>
                <ReferenceStartingPosition>216</ReferenceStartingPosition>
                <ReferenceEndingPosition>232</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1166</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>216-232</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKPIFKLPLGINITNFR</LinearSequence>
                                        <StartingPosition>216</StartingPosition>
                                        <EndingPosition>232</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1167</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>216-232</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKPIFKLPLGINITNFR</LinearSequence>
                                        <StartingPosition>216</StartingPosition>
                                        <EndingPosition>232</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1165</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>23.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>216-232</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKPIFKLPLGINITNFR</LinearSequence>
                                        <StartingPosition>216</StartingPosition>
                                        <EndingPosition>232</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P36</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LGINITNFRAILTAFSP</LinearSequence>
                        <StartingPosition>224</StartingPosition>
                        <EndingPosition>240</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>36167</EpitopeId>
                <ReferenceStartingPosition>224</ReferenceStartingPosition>
                <ReferenceEndingPosition>240</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1168</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>7.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>224-240</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LGINITNFRAILTAFSP</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>240</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1169</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>224-240</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LGINITNFRAILTAFSP</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>240</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1170</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>224-240</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LGINITNFRAILTAFSP</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>240</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P37</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RAILTAFSPAQDIWGTS</LinearSequence>
                        <StartingPosition>232</StartingPosition>
                        <EndingPosition>248</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>53116</EpitopeId>
                <ReferenceStartingPosition>232</ReferenceStartingPosition>
                <ReferenceEndingPosition>248</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1172</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>232-248</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RAILTAFSPAQDIWGTS</LinearSequence>
                                        <StartingPosition>232</StartingPosition>
                                        <EndingPosition>248</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1173</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>232-248</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RAILTAFSPAQDIWGTS</LinearSequence>
                                        <StartingPosition>232</StartingPosition>
                                        <EndingPosition>248</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1174</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>232-248</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RAILTAFSPAQDIWGTS</LinearSequence>
                                        <StartingPosition>232</StartingPosition>
                                        <EndingPosition>248</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P38</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SPAQDIWGTSAAAYFVG</LinearSequence>
                        <StartingPosition>239</StartingPosition>
                        <EndingPosition>255</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>59985</EpitopeId>
                <ReferenceStartingPosition>239</ReferenceStartingPosition>
                <ReferenceEndingPosition>255</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1176</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>239-255</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SPAQDIWGTSAAAYFVG</LinearSequence>
                                        <StartingPosition>239</StartingPosition>
                                        <EndingPosition>255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1177</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>239-255</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SPAQDIWGTSAAAYFVG</LinearSequence>
                                        <StartingPosition>239</StartingPosition>
                                        <EndingPosition>255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1175</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>239-255</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SPAQDIWGTSAAAYFVG</LinearSequence>
                                        <StartingPosition>239</StartingPosition>
                                        <EndingPosition>255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P39</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WGTSAAAYFVGYLKPTT</LinearSequence>
                        <StartingPosition>245</StartingPosition>
                        <EndingPosition>261</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>72519</EpitopeId>
                <ReferenceStartingPosition>245</ReferenceStartingPosition>
                <ReferenceEndingPosition>261</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1178</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>245-261</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WGTSAAAYFVGYLKPTT</LinearSequence>
                                        <StartingPosition>245</StartingPosition>
                                        <EndingPosition>261</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1179</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>245-261</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WGTSAAAYFVGYLKPTT</LinearSequence>
                                        <StartingPosition>245</StartingPosition>
                                        <EndingPosition>261</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1180</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>245-261</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WGTSAAAYFVGYLKPTT</LinearSequence>
                                        <StartingPosition>245</StartingPosition>
                                        <EndingPosition>261</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P40</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAYFVGYLKPTTFMLKY</LinearSequence>
                        <StartingPosition>250</StartingPosition>
                        <EndingPosition>266</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>525</EpitopeId>
                <ReferenceStartingPosition>250</ReferenceStartingPosition>
                <ReferenceEndingPosition>266</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1181</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>250-266</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAYFVGYLKPTTFMLKY</LinearSequence>
                                        <StartingPosition>250</StartingPosition>
                                        <EndingPosition>266</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1182</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>250-266</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAYFVGYLKPTTFMLKY</LinearSequence>
                                        <StartingPosition>250</StartingPosition>
                                        <EndingPosition>266</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1183</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>250-266</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAYFVGYLKPTTFMLKY</LinearSequence>
                                        <StartingPosition>250</StartingPosition>
                                        <EndingPosition>266</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P41</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KPTTFMLKYDENGTITD</LinearSequence>
                        <StartingPosition>258</StartingPosition>
                        <EndingPosition>274</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>32912</EpitopeId>
                <ReferenceStartingPosition>258</ReferenceStartingPosition>
                <ReferenceEndingPosition>274</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1186</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>258-274</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KPTTFMLKYDENGTITD</LinearSequence>
                                        <StartingPosition>258</StartingPosition>
                                        <EndingPosition>274</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1185</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>258-274</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KPTTFMLKYDENGTITD</LinearSequence>
                                        <StartingPosition>258</StartingPosition>
                                        <EndingPosition>274</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1184</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>7.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>258-274</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KPTTFMLKYDENGTITD</LinearSequence>
                                        <StartingPosition>258</StartingPosition>
                                        <EndingPosition>274</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P42</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MLKYDENGTITDAVDCS</LinearSequence>
                        <StartingPosition>263</StartingPosition>
                        <EndingPosition>279</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>41984</EpitopeId>
                <ReferenceStartingPosition>263</ReferenceStartingPosition>
                <ReferenceEndingPosition>279</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1187</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>263-279</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MLKYDENGTITDAVDCS</LinearSequence>
                                        <StartingPosition>263</StartingPosition>
                                        <EndingPosition>279</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1189</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>263-279</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MLKYDENGTITDAVDCS</LinearSequence>
                                        <StartingPosition>263</StartingPosition>
                                        <EndingPosition>279</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1188</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>263-279</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MLKYDENGTITDAVDCS</LinearSequence>
                                        <StartingPosition>263</StartingPosition>
                                        <EndingPosition>279</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P43</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TITDAVDCSQNPLAELK</LinearSequence>
                        <StartingPosition>271</StartingPosition>
                        <EndingPosition>287</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>64477</EpitopeId>
                <ReferenceStartingPosition>271</ReferenceStartingPosition>
                <ReferenceEndingPosition>287</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1192</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>271-287</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TITDAVDCSQNPLAELK</LinearSequence>
                                        <StartingPosition>271</StartingPosition>
                                        <EndingPosition>287</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1191</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>271-287</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TITDAVDCSQNPLAELK</LinearSequence>
                                        <StartingPosition>271</StartingPosition>
                                        <EndingPosition>287</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1190</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>21</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>271-287</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TITDAVDCSQNPLAELK</LinearSequence>
                                        <StartingPosition>271</StartingPosition>
                                        <EndingPosition>287</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P44</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CSQNPLAELKCSVKSFE</LinearSequence>
                        <StartingPosition>278</StartingPosition>
                        <EndingPosition>294</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7064</EpitopeId>
                <ReferenceStartingPosition>278</ReferenceStartingPosition>
                <ReferenceEndingPosition>294</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1195</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>278-294</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSQNPLAELKCSVKSFE</LinearSequence>
                                        <StartingPosition>278</StartingPosition>
                                        <EndingPosition>294</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1193</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>33</NumberOfSubjectsResponded>
                            <ResponseFrequency>78.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>278-294</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSQNPLAELKCSVKSFE</LinearSequence>
                                        <StartingPosition>278</StartingPosition>
                                        <EndingPosition>294</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1194</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>278-294</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSQNPLAELKCSVKSFE</LinearSequence>
                                        <StartingPosition>278</StartingPosition>
                                        <EndingPosition>294</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P45</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LKCSVKSFEIDKGIYQT</LinearSequence>
                        <StartingPosition>286</StartingPosition>
                        <EndingPosition>302</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>36815</EpitopeId>
                <ReferenceStartingPosition>286</ReferenceStartingPosition>
                <ReferenceEndingPosition>302</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1197</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>286-302</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKCSVKSFEIDKGIYQT</LinearSequence>
                                        <StartingPosition>286</StartingPosition>
                                        <EndingPosition>302</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1196</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>47.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>286-302</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKCSVKSFEIDKGIYQT</LinearSequence>
                                        <StartingPosition>286</StartingPosition>
                                        <EndingPosition>302</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1198</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>286-302</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKCSVKSFEIDKGIYQT</LinearSequence>
                                        <StartingPosition>286</StartingPosition>
                                        <EndingPosition>302</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P46</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EIDKGIYQTSNFRVVPS</LinearSequence>
                        <StartingPosition>294</StartingPosition>
                        <EndingPosition>310</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>12417</EpitopeId>
                <ReferenceStartingPosition>294</ReferenceStartingPosition>
                <ReferenceEndingPosition>310</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1199</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>21</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>294-310</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EIDKGIYQTSNFRVVPS</LinearSequence>
                                        <StartingPosition>294</StartingPosition>
                                        <EndingPosition>310</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1200</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>294-310</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EIDKGIYQTSNFRVVPS</LinearSequence>
                                        <StartingPosition>294</StartingPosition>
                                        <EndingPosition>310</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1201</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>294-310</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EIDKGIYQTSNFRVVPS</LinearSequence>
                                        <StartingPosition>294</StartingPosition>
                                        <EndingPosition>310</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P47</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TSNFRVVPSGDVVRFPN</LinearSequence>
                        <StartingPosition>302</StartingPosition>
                        <EndingPosition>318</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>66337</EpitopeId>
                <ReferenceStartingPosition>302</ReferenceStartingPosition>
                <ReferenceEndingPosition>318</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1204</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>47.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>302-318</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TSNFRVVPSGDVVRFPN</LinearSequence>
                                        <StartingPosition>302</StartingPosition>
                                        <EndingPosition>318</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1206</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>302-318</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TSNFRVVPSGDVVRFPN</LinearSequence>
                                        <StartingPosition>302</StartingPosition>
                                        <EndingPosition>318</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1205</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>302-318</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TSNFRVVPSGDVVRFPN</LinearSequence>
                                        <StartingPosition>302</StartingPosition>
                                        <EndingPosition>318</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P48</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGDVVRFPNITNLCPFG</LinearSequence>
                        <StartingPosition>310</StartingPosition>
                        <EndingPosition>326</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>58001</EpitopeId>
                <ReferenceStartingPosition>310</ReferenceStartingPosition>
                <ReferenceEndingPosition>326</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1208</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>310-326</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGDVVRFPNITNLCPFG</LinearSequence>
                                        <StartingPosition>310</StartingPosition>
                                        <EndingPosition>326</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1207</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>310-326</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGDVVRFPNITNLCPFG</LinearSequence>
                                        <StartingPosition>310</StartingPosition>
                                        <EndingPosition>326</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1209</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>310-326</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGDVVRFPNITNLCPFG</LinearSequence>
                                        <StartingPosition>310</StartingPosition>
                                        <EndingPosition>326</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P49</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VRFPNITNLCPFGEVFN</LinearSequence>
                        <StartingPosition>314</StartingPosition>
                        <EndingPosition>330</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>70719</EpitopeId>
                <ReferenceStartingPosition>314</ReferenceStartingPosition>
                <ReferenceEndingPosition>330</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1210</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>23.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>314-330</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VRFPNITNLCPFGEVFN</LinearSequence>
                                        <StartingPosition>314</StartingPosition>
                                        <EndingPosition>330</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1212</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>314-330</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VRFPNITNLCPFGEVFN</LinearSequence>
                                        <StartingPosition>314</StartingPosition>
                                        <EndingPosition>330</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1211</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>314-330</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VRFPNITNLCPFGEVFN</LinearSequence>
                                        <StartingPosition>314</StartingPosition>
                                        <EndingPosition>330</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P50</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LCPFGEVFNATKFPSVY</LinearSequence>
                        <StartingPosition>322</StartingPosition>
                        <EndingPosition>338</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>35083</EpitopeId>
                <ReferenceStartingPosition>322</ReferenceStartingPosition>
                <ReferenceEndingPosition>338</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1213</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>322-338</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LCPFGEVFNATKFPSVY</LinearSequence>
                                        <StartingPosition>322</StartingPosition>
                                        <EndingPosition>338</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1215</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>322-338</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LCPFGEVFNATKFPSVY</LinearSequence>
                                        <StartingPosition>322</StartingPosition>
                                        <EndingPosition>338</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1214</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>322-338</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LCPFGEVFNATKFPSVY</LinearSequence>
                                        <StartingPosition>322</StartingPosition>
                                        <EndingPosition>338</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P51</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FNATKFPSVYAWERKKI</LinearSequence>
                        <StartingPosition>329</StartingPosition>
                        <EndingPosition>345</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>17132</EpitopeId>
                <ReferenceStartingPosition>329</ReferenceStartingPosition>
                <ReferenceEndingPosition>345</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1216</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>329-345</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FNATKFPSVYAWERKKI</LinearSequence>
                                        <StartingPosition>329</StartingPosition>
                                        <EndingPosition>345</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1217</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>329-345</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FNATKFPSVYAWERKKI</LinearSequence>
                                        <StartingPosition>329</StartingPosition>
                                        <EndingPosition>345</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1218</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>329-345</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FNATKFPSVYAWERKKI</LinearSequence>
                                        <StartingPosition>329</StartingPosition>
                                        <EndingPosition>345</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P52</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PSVYAWERKKISNCVAD</LinearSequence>
                        <StartingPosition>335</StartingPosition>
                        <EndingPosition>351</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>49557</EpitopeId>
                <ReferenceStartingPosition>335</ReferenceStartingPosition>
                <ReferenceEndingPosition>351</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1220</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>335-351</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PSVYAWERKKISNCVAD</LinearSequence>
                                        <StartingPosition>335</StartingPosition>
                                        <EndingPosition>351</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1221</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>335-351</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PSVYAWERKKISNCVAD</LinearSequence>
                                        <StartingPosition>335</StartingPosition>
                                        <EndingPosition>351</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1219</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>28.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>335-351</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PSVYAWERKKISNCVAD</LinearSequence>
                                        <StartingPosition>335</StartingPosition>
                                        <EndingPosition>351</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P53</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KKISNCVADYSVLYNST</LinearSequence>
                        <StartingPosition>343</StartingPosition>
                        <EndingPosition>359</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>31581</EpitopeId>
                <ReferenceStartingPosition>343</ReferenceStartingPosition>
                <ReferenceEndingPosition>359</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1222</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>343-359</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KKISNCVADYSVLYNST</LinearSequence>
                                        <StartingPosition>343</StartingPosition>
                                        <EndingPosition>359</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1224</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>343-359</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KKISNCVADYSVLYNST</LinearSequence>
                                        <StartingPosition>343</StartingPosition>
                                        <EndingPosition>359</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1223</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>343-359</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KKISNCVADYSVLYNST</LinearSequence>
                                        <StartingPosition>343</StartingPosition>
                                        <EndingPosition>359</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P54</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YSVLYNSTFFSTFKCYG</LinearSequence>
                        <StartingPosition>352</StartingPosition>
                        <EndingPosition>368</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>75920</EpitopeId>
                <ReferenceStartingPosition>352</ReferenceStartingPosition>
                <ReferenceEndingPosition>368</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1225</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>28.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>352-368</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSVLYNSTFFSTFKCYG</LinearSequence>
                                        <StartingPosition>352</StartingPosition>
                                        <EndingPosition>368</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1227</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>352-368</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSVLYNSTFFSTFKCYG</LinearSequence>
                                        <StartingPosition>352</StartingPosition>
                                        <EndingPosition>368</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1226</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Sera were considered positive when the OD values were above the cutoff value (the mean OD of absorbance at 405 nm of sera from healthy blood donors plus 3 standard deviations). The positive rate of SARS sera for each peptide was calculated.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>352-368</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSVLYNSTFFSTFKCYG</LinearSequence>
                                        <StartingPosition>352</StartingPosition>
                                        <EndingPosition>368</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P55</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FFSTFKCYGVSATKLND</LinearSequence>
                        <StartingPosition>360</StartingPosition>
                        <EndingPosition>376</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>15903</EpitopeId>
                <ReferenceStartingPosition>360</ReferenceStartingPosition>
                <ReferenceEndingPosition>376</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1229</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>360-376</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FFSTFKCYGVSATKLND</LinearSequence>
                                        <StartingPosition>360</StartingPosition>
                                        <EndingPosition>376</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1228</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>360-376</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FFSTFKCYGVSATKLND</LinearSequence>
                                        <StartingPosition>360</StartingPosition>
                                        <EndingPosition>376</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1230</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>360-376</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FFSTFKCYGVSATKLND</LinearSequence>
                                        <StartingPosition>360</StartingPosition>
                                        <EndingPosition>376</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P56</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CYGVSATKLNDLCFSNV</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>382</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7383</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>382</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1231</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>366-382</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CYGVSATKLNDLCFSNV</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>382</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1232</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>366-382</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CYGVSATKLNDLCFSNV</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>382</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1233</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>366-382</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CYGVSATKLNDLCFSNV</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>382</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P57</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KLNDLCFSNVYADSFVV</LinearSequence>
                        <StartingPosition>373</StartingPosition>
                        <EndingPosition>389</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>32037</EpitopeId>
                <ReferenceStartingPosition>373</ReferenceStartingPosition>
                <ReferenceEndingPosition>389</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1235</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>373-389</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLNDLCFSNVYADSFVV</LinearSequence>
                                        <StartingPosition>373</StartingPosition>
                                        <EndingPosition>389</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1234</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>373-389</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLNDLCFSNVYADSFVV</LinearSequence>
                                        <StartingPosition>373</StartingPosition>
                                        <EndingPosition>389</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1236</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>373-389</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLNDLCFSNVYADSFVV</LinearSequence>
                                        <StartingPosition>373</StartingPosition>
                                        <EndingPosition>389</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P58</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NVYADSFVVKGDDVRQI</LinearSequence>
                        <StartingPosition>381</StartingPosition>
                        <EndingPosition>397</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>46522</EpitopeId>
                <ReferenceStartingPosition>381</ReferenceStartingPosition>
                <ReferenceEndingPosition>397</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1238</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>381-397</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVYADSFVVKGDDVRQI</LinearSequence>
                                        <StartingPosition>381</StartingPosition>
                                        <EndingPosition>397</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1239</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>381-397</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVYADSFVVKGDDVRQI</LinearSequence>
                                        <StartingPosition>381</StartingPosition>
                                        <EndingPosition>397</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1237</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>381-397</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVYADSFVVKGDDVRQI</LinearSequence>
                                        <StartingPosition>381</StartingPosition>
                                        <EndingPosition>397</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P59</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VKGDDVRQIAPGQTGVI</LinearSequence>
                        <StartingPosition>389</StartingPosition>
                        <EndingPosition>405</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>69223</EpitopeId>
                <ReferenceStartingPosition>389</ReferenceStartingPosition>
                <ReferenceEndingPosition>405</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1240</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>389-405</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VKGDDVRQIAPGQTGVI</LinearSequence>
                                        <StartingPosition>389</StartingPosition>
                                        <EndingPosition>405</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1242</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>389-405</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VKGDDVRQIAPGQTGVI</LinearSequence>
                                        <StartingPosition>389</StartingPosition>
                                        <EndingPosition>405</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1243</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>389-405</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VKGDDVRQIAPGQTGVI</LinearSequence>
                                        <StartingPosition>389</StartingPosition>
                                        <EndingPosition>405</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P60</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IAPGQTGVIADYNYKLP</LinearSequence>
                        <StartingPosition>397</StartingPosition>
                        <EndingPosition>413</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>25378</EpitopeId>
                <ReferenceStartingPosition>397</ReferenceStartingPosition>
                <ReferenceEndingPosition>413</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1247</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>397-413</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAPGQTGVIADYNYKLP</LinearSequence>
                                        <StartingPosition>397</StartingPosition>
                                        <EndingPosition>413</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1244</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>23.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>397-413</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAPGQTGVIADYNYKLP</LinearSequence>
                                        <StartingPosition>397</StartingPosition>
                                        <EndingPosition>413</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1246</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>397-413</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAPGQTGVIADYNYKLP</LinearSequence>
                                        <StartingPosition>397</StartingPosition>
                                        <EndingPosition>413</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P61</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IADYNYKLPDDFMGCVL</LinearSequence>
                        <StartingPosition>405</StartingPosition>
                        <EndingPosition>421</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>25250</EpitopeId>
                <ReferenceStartingPosition>405</ReferenceStartingPosition>
                <ReferenceEndingPosition>421</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1256</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>405-421</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IADYNYKLPDDFMGCVL</LinearSequence>
                                        <StartingPosition>405</StartingPosition>
                                        <EndingPosition>421</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1255</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>405-421</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IADYNYKLPDDFMGCVL</LinearSequence>
                                        <StartingPosition>405</StartingPosition>
                                        <EndingPosition>421</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1254</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>405-421</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IADYNYKLPDDFMGCVL</LinearSequence>
                                        <StartingPosition>405</StartingPosition>
                                        <EndingPosition>421</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P62</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KLPDDFMGCVLAWNTRN</LinearSequence>
                        <StartingPosition>411</StartingPosition>
                        <EndingPosition>427</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>32070</EpitopeId>
                <ReferenceStartingPosition>411</ReferenceStartingPosition>
                <ReferenceEndingPosition>427</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1258</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>411-427</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLPDDFMGCVLAWNTRN</LinearSequence>
                                        <StartingPosition>411</StartingPosition>
                                        <EndingPosition>427</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1259</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>411-427</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLPDDFMGCVLAWNTRN</LinearSequence>
                                        <StartingPosition>411</StartingPosition>
                                        <EndingPosition>427</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1257</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>411-427</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLPDDFMGCVLAWNTRN</LinearSequence>
                                        <StartingPosition>411</StartingPosition>
                                        <EndingPosition>427</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P63</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CVLAWNTRNIDATSTGN</LinearSequence>
                        <StartingPosition>419</StartingPosition>
                        <EndingPosition>435</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7280</EpitopeId>
                <ReferenceStartingPosition>419</ReferenceStartingPosition>
                <ReferenceEndingPosition>435</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1262</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>419-435</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CVLAWNTRNIDATSTGN</LinearSequence>
                                        <StartingPosition>419</StartingPosition>
                                        <EndingPosition>435</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1260</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>419-435</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CVLAWNTRNIDATSTGN</LinearSequence>
                                        <StartingPosition>419</StartingPosition>
                                        <EndingPosition>435</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1261</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>419-435</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CVLAWNTRNIDATSTGN</LinearSequence>
                                        <StartingPosition>419</StartingPosition>
                                        <EndingPosition>435</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P64</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NIDATSTGNYNYKYRYL</LinearSequence>
                        <StartingPosition>427</StartingPosition>
                        <EndingPosition>443</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>44198</EpitopeId>
                <ReferenceStartingPosition>427</ReferenceStartingPosition>
                <ReferenceEndingPosition>443</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1263</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>427-443</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NIDATSTGNYNYKYRYL</LinearSequence>
                                        <StartingPosition>427</StartingPosition>
                                        <EndingPosition>443</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1265</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>427-443</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NIDATSTGNYNYKYRYL</LinearSequence>
                                        <StartingPosition>427</StartingPosition>
                                        <EndingPosition>443</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1264</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>427-443</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NIDATSTGNYNYKYRYL</LinearSequence>
                                        <StartingPosition>427</StartingPosition>
                                        <EndingPosition>443</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P65</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NYNYKYRYLRHGKLRPF</LinearSequence>
                        <StartingPosition>435</StartingPosition>
                        <EndingPosition>451</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>46681</EpitopeId>
                <ReferenceStartingPosition>435</ReferenceStartingPosition>
                <ReferenceEndingPosition>451</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1268</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>435-451</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NYNYKYRYLRHGKLRPF</LinearSequence>
                                        <StartingPosition>435</StartingPosition>
                                        <EndingPosition>451</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1266</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>23.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>435-451</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NYNYKYRYLRHGKLRPF</LinearSequence>
                                        <StartingPosition>435</StartingPosition>
                                        <EndingPosition>451</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1267</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>435-451</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NYNYKYRYLRHGKLRPF</LinearSequence>
                                        <StartingPosition>435</StartingPosition>
                                        <EndingPosition>451</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P66</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LRHGKLRPFERDISNVP</LinearSequence>
                        <StartingPosition>443</StartingPosition>
                        <EndingPosition>459</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>39110</EpitopeId>
                <ReferenceStartingPosition>443</ReferenceStartingPosition>
                <ReferenceEndingPosition>459</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1271</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>443-459</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LRHGKLRPFERDISNVP</LinearSequence>
                                        <StartingPosition>443</StartingPosition>
                                        <EndingPosition>459</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1269</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>443-459</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LRHGKLRPFERDISNVP</LinearSequence>
                                        <StartingPosition>443</StartingPosition>
                                        <EndingPosition>459</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1270</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>443-459</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LRHGKLRPFERDISNVP</LinearSequence>
                                        <StartingPosition>443</StartingPosition>
                                        <EndingPosition>459</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P67</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RPFERDISNVPFSPDGK</LinearSequence>
                        <StartingPosition>449</StartingPosition>
                        <EndingPosition>465</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>55149</EpitopeId>
                <ReferenceStartingPosition>449</ReferenceStartingPosition>
                <ReferenceEndingPosition>465</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1274</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>449-465</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPFERDISNVPFSPDGK</LinearSequence>
                                        <StartingPosition>449</StartingPosition>
                                        <EndingPosition>465</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1272</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>449-465</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPFERDISNVPFSPDGK</LinearSequence>
                                        <StartingPosition>449</StartingPosition>
                                        <EndingPosition>465</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1273</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>449-465</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPFERDISNVPFSPDGK</LinearSequence>
                                        <StartingPosition>449</StartingPosition>
                                        <EndingPosition>465</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P68</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SNVPFSPDGKPCTPPAL</LinearSequence>
                        <StartingPosition>456</StartingPosition>
                        <EndingPosition>472</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>59944</EpitopeId>
                <ReferenceStartingPosition>456</ReferenceStartingPosition>
                <ReferenceEndingPosition>472</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1276</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>456-472</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SNVPFSPDGKPCTPPAL</LinearSequence>
                                        <StartingPosition>456</StartingPosition>
                                        <EndingPosition>472</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1277</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>456-472</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SNVPFSPDGKPCTPPAL</LinearSequence>
                                        <StartingPosition>456</StartingPosition>
                                        <EndingPosition>472</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1275</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>456-472</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SNVPFSPDGKPCTPPAL</LinearSequence>
                                        <StartingPosition>456</StartingPosition>
                                        <EndingPosition>472</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P69</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SPDGKPCTPPALNCYWP</LinearSequence>
                        <StartingPosition>461</StartingPosition>
                        <EndingPosition>477</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>60014</EpitopeId>
                <ReferenceStartingPosition>461</ReferenceStartingPosition>
                <ReferenceEndingPosition>477</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1280</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>461-477</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SPDGKPCTPPALNCYWP</LinearSequence>
                                        <StartingPosition>461</StartingPosition>
                                        <EndingPosition>477</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1278</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>461-477</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SPDGKPCTPPALNCYWP</LinearSequence>
                                        <StartingPosition>461</StartingPosition>
                                        <EndingPosition>477</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1279</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>461-477</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SPDGKPCTPPALNCYWP</LinearSequence>
                                        <StartingPosition>461</StartingPosition>
                                        <EndingPosition>477</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P70</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CTPPALNCYWPLNDYGF</LinearSequence>
                        <StartingPosition>467</StartingPosition>
                        <EndingPosition>483</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7193</EpitopeId>
                <ReferenceStartingPosition>467</ReferenceStartingPosition>
                <ReferenceEndingPosition>483</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1282</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>467-483</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTPPALNCYWPLNDYGF</LinearSequence>
                                        <StartingPosition>467</StartingPosition>
                                        <EndingPosition>483</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1281</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>467-483</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTPPALNCYWPLNDYGF</LinearSequence>
                                        <StartingPosition>467</StartingPosition>
                                        <EndingPosition>483</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1283</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>467-483</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTPPALNCYWPLNDYGF</LinearSequence>
                                        <StartingPosition>467</StartingPosition>
                                        <EndingPosition>483</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P71</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CYWPLNDYGFYTTTGIG</LinearSequence>
                        <StartingPosition>474</StartingPosition>
                        <EndingPosition>490</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7452</EpitopeId>
                <ReferenceStartingPosition>474</ReferenceStartingPosition>
                <ReferenceEndingPosition>490</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1284</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>474-490</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CYWPLNDYGFYTTTGIG</LinearSequence>
                                        <StartingPosition>474</StartingPosition>
                                        <EndingPosition>490</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1285</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>474-490</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CYWPLNDYGFYTTTGIG</LinearSequence>
                                        <StartingPosition>474</StartingPosition>
                                        <EndingPosition>490</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1286</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>474-490</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CYWPLNDYGFYTTTGIG</LinearSequence>
                                        <StartingPosition>474</StartingPosition>
                                        <EndingPosition>490</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P72</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GFYTTTGIGYQPYRVVV</LinearSequence>
                        <StartingPosition>482</StartingPosition>
                        <EndingPosition>498</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>19657</EpitopeId>
                <ReferenceStartingPosition>482</ReferenceStartingPosition>
                <ReferenceEndingPosition>498</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1289</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>482-498</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GFYTTTGIGYQPYRVVV</LinearSequence>
                                        <StartingPosition>482</StartingPosition>
                                        <EndingPosition>498</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1288</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>482-498</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GFYTTTGIGYQPYRVVV</LinearSequence>
                                        <StartingPosition>482</StartingPosition>
                                        <EndingPosition>498</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1287</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>482-498</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GFYTTTGIGYQPYRVVV</LinearSequence>
                                        <StartingPosition>482</StartingPosition>
                                        <EndingPosition>498</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P73</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GYQPYRVVVLSFELLNA</LinearSequence>
                        <StartingPosition>490</StartingPosition>
                        <EndingPosition>506</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>23437</EpitopeId>
                <ReferenceStartingPosition>490</ReferenceStartingPosition>
                <ReferenceEndingPosition>505</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1290</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>490-505</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GYQPYRVVVLSFELLNA</LinearSequence>
                                        <StartingPosition>490</StartingPosition>
                                        <EndingPosition>506</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1291</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>490-505</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GYQPYRVVVLSFELLNA</LinearSequence>
                                        <StartingPosition>490</StartingPosition>
                                        <EndingPosition>506</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1292</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>490-505</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GYQPYRVVVLSFELLNA</LinearSequence>
                                        <StartingPosition>490</StartingPosition>
                                        <EndingPosition>506</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P74</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VLSFELLNAPATVCGPK</LinearSequence>
                        <StartingPosition>498</StartingPosition>
                        <EndingPosition>514</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>69760</EpitopeId>
                <ReferenceStartingPosition>498</ReferenceStartingPosition>
                <ReferenceEndingPosition>514</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1294</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>498-514</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLSFELLNAPATVCGPK</LinearSequence>
                                        <StartingPosition>498</StartingPosition>
                                        <EndingPosition>514</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1293</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>498-514</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLSFELLNAPATVCGPK</LinearSequence>
                                        <StartingPosition>498</StartingPosition>
                                        <EndingPosition>514</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1295</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>498-514</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLSFELLNAPATVCGPK</LinearSequence>
                                        <StartingPosition>498</StartingPosition>
                                        <EndingPosition>514</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P75</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NAPATVCGPKLSTDLIK</LinearSequence>
                        <StartingPosition>505</StartingPosition>
                        <EndingPosition>521</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43264</EpitopeId>
                <ReferenceStartingPosition>505</ReferenceStartingPosition>
                <ReferenceEndingPosition>521</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1296</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>505-521</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAPATVCGPKLSTDLIK</LinearSequence>
                                        <StartingPosition>505</StartingPosition>
                                        <EndingPosition>521</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1298</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>505-521</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAPATVCGPKLSTDLIK</LinearSequence>
                                        <StartingPosition>505</StartingPosition>
                                        <EndingPosition>521</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1297</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>505-521</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAPATVCGPKLSTDLIK</LinearSequence>
                                        <StartingPosition>505</StartingPosition>
                                        <EndingPosition>521</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P76</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CGPKLSTDLIKNQCVNF</LinearSequence>
                        <StartingPosition>511</StartingPosition>
                        <EndingPosition>527</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>6332</EpitopeId>
                <ReferenceStartingPosition>511</ReferenceStartingPosition>
                <ReferenceEndingPosition>527</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1300</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>511-527</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CGPKLSTDLIKNQCVNF</LinearSequence>
                                        <StartingPosition>511</StartingPosition>
                                        <EndingPosition>527</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1301</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>511-527</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CGPKLSTDLIKNQCVNF</LinearSequence>
                                        <StartingPosition>511</StartingPosition>
                                        <EndingPosition>527</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1299</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>511-527</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CGPKLSTDLIKNQCVNF</LinearSequence>
                                        <StartingPosition>511</StartingPosition>
                                        <EndingPosition>527</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P77</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LIKNQCVNFNFNGLTGT</LinearSequence>
                        <StartingPosition>519</StartingPosition>
                        <EndingPosition>535</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>36579</EpitopeId>
                <ReferenceStartingPosition>519</ReferenceStartingPosition>
                <ReferenceEndingPosition>535</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1304</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>519-535</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LIKNQCVNFNFNGLTGT</LinearSequence>
                                        <StartingPosition>519</StartingPosition>
                                        <EndingPosition>535</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1302</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>7.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>519-535</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LIKNQCVNFNFNGLTGT</LinearSequence>
                                        <StartingPosition>519</StartingPosition>
                                        <EndingPosition>535</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1303</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>519-535</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LIKNQCVNFNFNGLTGT</LinearSequence>
                                        <StartingPosition>519</StartingPosition>
                                        <EndingPosition>535</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P78</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NFNGLTGTGVLTPSSKR</LinearSequence>
                        <StartingPosition>528</StartingPosition>
                        <EndingPosition>544</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43893</EpitopeId>
                <ReferenceStartingPosition>528</ReferenceStartingPosition>
                <ReferenceEndingPosition>544</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1307</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>528-544</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFNGLTGTGVLTPSSKR</LinearSequence>
                                        <StartingPosition>528</StartingPosition>
                                        <EndingPosition>544</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1306</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>528-544</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFNGLTGTGVLTPSSKR</LinearSequence>
                                        <StartingPosition>528</StartingPosition>
                                        <EndingPosition>544</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1305</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>29</NumberOfSubjectsResponded>
                            <ResponseFrequency>69</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>528-544</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFNGLTGTGVLTPSSKR</LinearSequence>
                                        <StartingPosition>528</StartingPosition>
                                        <EndingPosition>544</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P79</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GVLTPSSKRFQPFQQFG</LinearSequence>
                        <StartingPosition>536</StartingPosition>
                        <EndingPosition>552</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>23051</EpitopeId>
                <ReferenceStartingPosition>536</ReferenceStartingPosition>
                <ReferenceEndingPosition>552</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1310</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>536-552</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVLTPSSKRFQPFQQFG</LinearSequence>
                                        <StartingPosition>536</StartingPosition>
                                        <EndingPosition>552</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1308</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>34</NumberOfSubjectsResponded>
                            <ResponseFrequency>81</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>536-552</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVLTPSSKRFQPFQQFG</LinearSequence>
                                        <StartingPosition>536</StartingPosition>
                                        <EndingPosition>552</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1309</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>536-552</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVLTPSSKRFQPFQQFG</LinearSequence>
                                        <StartingPosition>536</StartingPosition>
                                        <EndingPosition>552</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P80</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RFQPFQQFGRDVSDFTD</LinearSequence>
                        <StartingPosition>544</StartingPosition>
                        <EndingPosition>560</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>53766</EpitopeId>
                <ReferenceStartingPosition>544</ReferenceStartingPosition>
                <ReferenceEndingPosition>560</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1312</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>544-560</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RFQPFQQFGRDVSDFTD</LinearSequence>
                                        <StartingPosition>544</StartingPosition>
                                        <EndingPosition>560</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1311</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>27</NumberOfSubjectsResponded>
                            <ResponseFrequency>64.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>544-560</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RFQPFQQFGRDVSDFTD</LinearSequence>
                                        <StartingPosition>544</StartingPosition>
                                        <EndingPosition>560</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1313</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>544-560</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RFQPFQQFGRDVSDFTD</LinearSequence>
                                        <StartingPosition>544</StartingPosition>
                                        <EndingPosition>560</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P81</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QFGRDVSDFTDSVRDPK</LinearSequence>
                        <StartingPosition>550</StartingPosition>
                        <EndingPosition>566</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>50767</EpitopeId>
                <ReferenceStartingPosition>550</ReferenceStartingPosition>
                <ReferenceEndingPosition>566</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1315</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>550-566</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QFGRDVSDFTDSVRDPK</LinearSequence>
                                        <StartingPosition>550</StartingPosition>
                                        <EndingPosition>566</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1316</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>550-566</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QFGRDVSDFTDSVRDPK</LinearSequence>
                                        <StartingPosition>550</StartingPosition>
                                        <EndingPosition>566</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1314</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>32</NumberOfSubjectsResponded>
                            <ResponseFrequency>76.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>550-566</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QFGRDVSDFTDSVRDPK</LinearSequence>
                                        <StartingPosition>550</StartingPosition>
                                        <EndingPosition>566</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P82</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FTDSVRDPKTSEILDIS</LinearSequence>
                        <StartingPosition>558</StartingPosition>
                        <EndingPosition>574</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>17929</EpitopeId>
                <ReferenceStartingPosition>558</ReferenceStartingPosition>
                <ReferenceEndingPosition>574</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1319</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>558-574</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FTDSVRDPKTSEILDIS</LinearSequence>
                                        <StartingPosition>558</StartingPosition>
                                        <EndingPosition>574</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1317</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>33</NumberOfSubjectsResponded>
                            <ResponseFrequency>78.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>558-574</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FTDSVRDPKTSEILDIS</LinearSequence>
                                        <StartingPosition>558</StartingPosition>
                                        <EndingPosition>574</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1318</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>558-574</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FTDSVRDPKTSEILDIS</LinearSequence>
                                        <StartingPosition>558</StartingPosition>
                                        <EndingPosition>574</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P83</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PKTSEILDISPCAFGGV</LinearSequence>
                        <StartingPosition>565</StartingPosition>
                        <EndingPosition>581</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>48155</EpitopeId>
                <ReferenceStartingPosition>565</ReferenceStartingPosition>
                <ReferenceEndingPosition>581</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1321</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>565-581</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PKTSEILDISPCAFGGV</LinearSequence>
                                        <StartingPosition>565</StartingPosition>
                                        <EndingPosition>581</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1322</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>565-581</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PKTSEILDISPCAFGGV</LinearSequence>
                                        <StartingPosition>565</StartingPosition>
                                        <EndingPosition>581</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1320</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>33</NumberOfSubjectsResponded>
                            <ResponseFrequency>78.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>565-581</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PKTSEILDISPCAFGGV</LinearSequence>
                                        <StartingPosition>565</StartingPosition>
                                        <EndingPosition>581</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P84</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ISPCAFGGVSVITPGTN</LinearSequence>
                        <StartingPosition>573</StartingPosition>
                        <EndingPosition>589</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>28643</EpitopeId>
                <ReferenceStartingPosition>573</ReferenceStartingPosition>
                <ReferenceEndingPosition>589</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1324</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>573-589</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ISPCAFGGVSVITPGTN</LinearSequence>
                                        <StartingPosition>573</StartingPosition>
                                        <EndingPosition>589</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1323</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>23</NumberOfSubjectsResponded>
                            <ResponseFrequency>54.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>573-589</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ISPCAFGGVSVITPGTN</LinearSequence>
                                        <StartingPosition>573</StartingPosition>
                                        <EndingPosition>589</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1325</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>573-589</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ISPCAFGGVSVITPGTN</LinearSequence>
                                        <StartingPosition>573</StartingPosition>
                                        <EndingPosition>589</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P85</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VSVITPGTNASSEVAVL</LinearSequence>
                        <StartingPosition>581</StartingPosition>
                        <EndingPosition>597</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>71189</EpitopeId>
                <ReferenceStartingPosition>581</ReferenceStartingPosition>
                <ReferenceEndingPosition>597</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1333</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>581-597</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VSVITPGTNASSEVAVL</LinearSequence>
                                        <StartingPosition>581</StartingPosition>
                                        <EndingPosition>597</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1331</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>23</NumberOfSubjectsResponded>
                            <ResponseFrequency>54.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>581-597</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VSVITPGTNASSEVAVL</LinearSequence>
                                        <StartingPosition>581</StartingPosition>
                                        <EndingPosition>597</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1332</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>581-597</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VSVITPGTNASSEVAVL</LinearSequence>
                                        <StartingPosition>581</StartingPosition>
                                        <EndingPosition>597</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P86</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NASSEVAVLYQDVNCTD</LinearSequence>
                        <StartingPosition>589</StartingPosition>
                        <EndingPosition>605</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43313</EpitopeId>
                <ReferenceStartingPosition>589</ReferenceStartingPosition>
                <ReferenceEndingPosition>605</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1334</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>19</NumberOfSubjectsResponded>
                            <ResponseFrequency>45.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>589-605</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NASSEVAVLYQDVNCTD</LinearSequence>
                                        <StartingPosition>589</StartingPosition>
                                        <EndingPosition>605</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1336</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>589-605</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NASSEVAVLYQDVNCTD</LinearSequence>
                                        <StartingPosition>589</StartingPosition>
                                        <EndingPosition>605</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1335</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>589-605</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NASSEVAVLYQDVNCTD</LinearSequence>
                                        <StartingPosition>589</StartingPosition>
                                        <EndingPosition>605</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P87</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LYQDVNCTDVSTAIHAD</LinearSequence>
                        <StartingPosition>597</StartingPosition>
                        <EndingPosition>613</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>40905</EpitopeId>
                <ReferenceStartingPosition>597</ReferenceStartingPosition>
                <ReferenceEndingPosition>613</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1339</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>597-613</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQDVNCTDVSTAIHAD</LinearSequence>
                                        <StartingPosition>597</StartingPosition>
                                        <EndingPosition>613</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1338</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>597-613</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQDVNCTDVSTAIHAD</LinearSequence>
                                        <StartingPosition>597</StartingPosition>
                                        <EndingPosition>613</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1337</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>24</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>597-613</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYQDVNCTDVSTAIHAD</LinearSequence>
                                        <StartingPosition>597</StartingPosition>
                                        <EndingPosition>613</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P88</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CTDVSTAIHADQLTPAW</LinearSequence>
                        <StartingPosition>603</StartingPosition>
                        <EndingPosition>619</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7128</EpitopeId>
                <ReferenceStartingPosition>603</ReferenceStartingPosition>
                <ReferenceEndingPosition>619</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1341</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>603-619</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTDVSTAIHADQLTPAW</LinearSequence>
                                        <StartingPosition>603</StartingPosition>
                                        <EndingPosition>619</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1342</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>603-619</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTDVSTAIHADQLTPAW</LinearSequence>
                                        <StartingPosition>603</StartingPosition>
                                        <EndingPosition>619</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1340</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>34</NumberOfSubjectsResponded>
                            <ResponseFrequency>81</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>603-619</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CTDVSTAIHADQLTPAW</LinearSequence>
                                        <StartingPosition>603</StartingPosition>
                                        <EndingPosition>619</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P89</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HADQLTPAWRIYSTGNN</LinearSequence>
                        <StartingPosition>611</StartingPosition>
                        <EndingPosition>627</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>23520</EpitopeId>
                <ReferenceStartingPosition>611</ReferenceStartingPosition>
                <ReferenceEndingPosition>627</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1343</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>25</NumberOfSubjectsResponded>
                            <ResponseFrequency>59.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>611-627</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HADQLTPAWRIYSTGNN</LinearSequence>
                                        <StartingPosition>611</StartingPosition>
                                        <EndingPosition>627</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1344</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>611-627</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HADQLTPAWRIYSTGNN</LinearSequence>
                                        <StartingPosition>611</StartingPosition>
                                        <EndingPosition>627</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1345</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>611-627</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HADQLTPAWRIYSTGNN</LinearSequence>
                                        <StartingPosition>611</StartingPosition>
                                        <EndingPosition>627</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P90</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WRIYSTGNNVFQTQAGC</LinearSequence>
                        <StartingPosition>619</StartingPosition>
                        <EndingPosition>635</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>73036</EpitopeId>
                <ReferenceStartingPosition>619</ReferenceStartingPosition>
                <ReferenceEndingPosition>635</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1346</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>17</NumberOfSubjectsResponded>
                            <ResponseFrequency>40.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>619-635</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WRIYSTGNNVFQTQAGC</LinearSequence>
                                        <StartingPosition>619</StartingPosition>
                                        <EndingPosition>635</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1348</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>619-635</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WRIYSTGNNVFQTQAGC</LinearSequence>
                                        <StartingPosition>619</StartingPosition>
                                        <EndingPosition>635</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1347</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>619-635</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WRIYSTGNNVFQTQAGC</LinearSequence>
                                        <StartingPosition>619</StartingPosition>
                                        <EndingPosition>635</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P91</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NVFQTQAGCLIGAEHVD</LinearSequence>
                        <StartingPosition>627</StartingPosition>
                        <EndingPosition>643</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>46379</EpitopeId>
                <ReferenceStartingPosition>627</ReferenceStartingPosition>
                <ReferenceEndingPosition>643</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1350</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>627-643</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVFQTQAGCLIGAEHVD</LinearSequence>
                                        <StartingPosition>627</StartingPosition>
                                        <EndingPosition>643</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1349</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>627-643</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVFQTQAGCLIGAEHVD</LinearSequence>
                                        <StartingPosition>627</StartingPosition>
                                        <EndingPosition>643</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1351</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>627-643</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NVFQTQAGCLIGAEHVD</LinearSequence>
                                        <StartingPosition>627</StartingPosition>
                                        <EndingPosition>643</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P92</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AGCLIGAEHVDTSYECD</LinearSequence>
                        <StartingPosition>633</StartingPosition>
                        <EndingPosition>649</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>1460</EpitopeId>
                <ReferenceStartingPosition>633</ReferenceStartingPosition>
                <ReferenceEndingPosition>649</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1353</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>633-649</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGCLIGAEHVDTSYECD</LinearSequence>
                                        <StartingPosition>633</StartingPosition>
                                        <EndingPosition>649</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1354</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>633-649</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGCLIGAEHVDTSYECD</LinearSequence>
                                        <StartingPosition>633</StartingPosition>
                                        <EndingPosition>649</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1352</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>47.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>633-649</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGCLIGAEHVDTSYECD</LinearSequence>
                                        <StartingPosition>633</StartingPosition>
                                        <EndingPosition>649</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P93</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HVDTSYECDIPIGAGIC</LinearSequence>
                        <StartingPosition>641</StartingPosition>
                        <EndingPosition>657</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>25031</EpitopeId>
                <ReferenceStartingPosition>641</ReferenceStartingPosition>
                <ReferenceEndingPosition>657</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1357</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>641-657</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HVDTSYECDIPIGAGIC</LinearSequence>
                                        <StartingPosition>641</StartingPosition>
                                        <EndingPosition>657</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1355</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>641-657</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HVDTSYECDIPIGAGIC</LinearSequence>
                                        <StartingPosition>641</StartingPosition>
                                        <EndingPosition>657</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1356</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>641-657</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HVDTSYECDIPIGAGIC</LinearSequence>
                                        <StartingPosition>641</StartingPosition>
                                        <EndingPosition>657</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P94</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CDIPIGAGICASYHTVS</LinearSequence>
                        <StartingPosition>648</StartingPosition>
                        <EndingPosition>664</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>6110</EpitopeId>
                <ReferenceStartingPosition>648</ReferenceStartingPosition>
                <ReferenceEndingPosition>664</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1359</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>648-664</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CDIPIGAGICASYHTVS</LinearSequence>
                                        <StartingPosition>648</StartingPosition>
                                        <EndingPosition>664</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1358</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>28.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>648-664</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CDIPIGAGICASYHTVS</LinearSequence>
                                        <StartingPosition>648</StartingPosition>
                                        <EndingPosition>664</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1360</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>648-664</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CDIPIGAGICASYHTVS</LinearSequence>
                                        <StartingPosition>648</StartingPosition>
                                        <EndingPosition>664</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P95</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CASYHTVSLLRSTSQKS</LinearSequence>
                        <StartingPosition>657</StartingPosition>
                        <EndingPosition>673</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>6040</EpitopeId>
                <ReferenceStartingPosition>657</ReferenceStartingPosition>
                <ReferenceEndingPosition>673</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1362</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>657-673</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CASYHTVSLLRSTSQKS</LinearSequence>
                                        <StartingPosition>657</StartingPosition>
                                        <EndingPosition>673</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1361</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>657-673</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CASYHTVSLLRSTSQKS</LinearSequence>
                                        <StartingPosition>657</StartingPosition>
                                        <EndingPosition>673</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1363</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>657-673</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CASYHTVSLLRSTSQKS</LinearSequence>
                                        <StartingPosition>657</StartingPosition>
                                        <EndingPosition>673</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P96</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LLRSTSQKSIVAYTMSL</LinearSequence>
                        <StartingPosition>665</StartingPosition>
                        <EndingPosition>681</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>37758</EpitopeId>
                <ReferenceStartingPosition>665</ReferenceStartingPosition>
                <ReferenceEndingPosition>681</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1366</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>665-681</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LLRSTSQKSIVAYTMSL</LinearSequence>
                                        <StartingPosition>665</StartingPosition>
                                        <EndingPosition>681</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1365</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>665-681</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LLRSTSQKSIVAYTMSL</LinearSequence>
                                        <StartingPosition>665</StartingPosition>
                                        <EndingPosition>681</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1364</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>28.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>665-681</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LLRSTSQKSIVAYTMSL</LinearSequence>
                                        <StartingPosition>665</StartingPosition>
                                        <EndingPosition>681</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P97</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KSIVAYTMSLGADSSIA</LinearSequence>
                        <StartingPosition>672</StartingPosition>
                        <EndingPosition>688</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>33358</EpitopeId>
                <ReferenceStartingPosition>672</ReferenceStartingPosition>
                <ReferenceEndingPosition>688</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1368</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>672-688</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KSIVAYTMSLGADSSIA</LinearSequence>
                                        <StartingPosition>672</StartingPosition>
                                        <EndingPosition>688</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1369</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>672-688</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KSIVAYTMSLGADSSIA</LinearSequence>
                                        <StartingPosition>672</StartingPosition>
                                        <EndingPosition>688</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1367</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>23.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>672-688</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KSIVAYTMSLGADSSIA</LinearSequence>
                                        <StartingPosition>672</StartingPosition>
                                        <EndingPosition>688</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P98</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SLGADSSIAYSNNTIAI</LinearSequence>
                        <StartingPosition>680</StartingPosition>
                        <EndingPosition>696</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>59120</EpitopeId>
                <ReferenceStartingPosition>680</ReferenceStartingPosition>
                <ReferenceEndingPosition>696</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1371</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>680-696</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLGADSSIAYSNNTIAI</LinearSequence>
                                        <StartingPosition>680</StartingPosition>
                                        <EndingPosition>696</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1370</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>680-696</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLGADSSIAYSNNTIAI</LinearSequence>
                                        <StartingPosition>680</StartingPosition>
                                        <EndingPosition>696</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1372</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>680-696</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLGADSSIAYSNNTIAI</LinearSequence>
                                        <StartingPosition>680</StartingPosition>
                                        <EndingPosition>696</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P99</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AYSNNTIAIPTNFSISI</LinearSequence>
                        <StartingPosition>688</StartingPosition>
                        <EndingPosition>704</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>5927</EpitopeId>
                <ReferenceStartingPosition>688</ReferenceStartingPosition>
                <ReferenceEndingPosition>704</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1374</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>688-704</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AYSNNTIAIPTNFSISI</LinearSequence>
                                        <StartingPosition>688</StartingPosition>
                                        <EndingPosition>704</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1375</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>688-704</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AYSNNTIAIPTNFSISI</LinearSequence>
                                        <StartingPosition>688</StartingPosition>
                                        <EndingPosition>704</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1373</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>688-704</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AYSNNTIAIPTNFSISI</LinearSequence>
                                        <StartingPosition>688</StartingPosition>
                                        <EndingPosition>704</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P100</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AIPTNFSISITTEVMPV</LinearSequence>
                        <StartingPosition>695</StartingPosition>
                        <EndingPosition>711</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>2053</EpitopeId>
                <ReferenceStartingPosition>695</ReferenceStartingPosition>
                <ReferenceEndingPosition>711</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1376</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>695-711</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AIPTNFSISITTEVMPV</LinearSequence>
                                        <StartingPosition>695</StartingPosition>
                                        <EndingPosition>711</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1377</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>695-711</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AIPTNFSISITTEVMPV</LinearSequence>
                                        <StartingPosition>695</StartingPosition>
                                        <EndingPosition>711</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1378</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>695-711</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AIPTNFSISITTEVMPV</LinearSequence>
                                        <StartingPosition>695</StartingPosition>
                                        <EndingPosition>711</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P101</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ISITTEVMPVSMAKTSV</LinearSequence>
                        <StartingPosition>702</StartingPosition>
                        <EndingPosition>718</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>28548</EpitopeId>
                <ReferenceStartingPosition>702</ReferenceStartingPosition>
                <ReferenceEndingPosition>718</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1379</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>702-718</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ISITTEVMPVSMAKTSV</LinearSequence>
                                        <StartingPosition>702</StartingPosition>
                                        <EndingPosition>718</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1381</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>702-718</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ISITTEVMPVSMAKTSV</LinearSequence>
                                        <StartingPosition>702</StartingPosition>
                                        <EndingPosition>718</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1380</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>702-718</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ISITTEVMPVSMAKTSV</LinearSequence>
                                        <StartingPosition>702</StartingPosition>
                                        <EndingPosition>718</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P102</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PVSMAKTSVDCNMYICGDS</LinearSequence>
                        <StartingPosition>710</StartingPosition>
                        <EndingPosition>728</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>49968</EpitopeId>
                <ReferenceStartingPosition>710</ReferenceStartingPosition>
                <ReferenceEndingPosition>728</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1384</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>710-728</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PVSMAKTSVDCNMYICGDS</LinearSequence>
                                        <StartingPosition>710</StartingPosition>
                                        <EndingPosition>728</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1383</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>710-728</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PVSMAKTSVDCNMYICGDS</LinearSequence>
                                        <StartingPosition>710</StartingPosition>
                                        <EndingPosition>728</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1382</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>710-728</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PVSMAKTSVDCNMYICGDS</LinearSequence>
                                        <StartingPosition>710</StartingPosition>
                                        <EndingPosition>728</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P103</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KTSVDCNMYICGDSTEC</LinearSequence>
                        <StartingPosition>715</StartingPosition>
                        <EndingPosition>731</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>33874</EpitopeId>
                <ReferenceStartingPosition>715</ReferenceStartingPosition>
                <ReferenceEndingPosition>731</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1385</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>715-731</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KTSVDCNMYICGDSTEC</LinearSequence>
                                        <StartingPosition>715</StartingPosition>
                                        <EndingPosition>731</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1386</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>715-731</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KTSVDCNMYICGDSTEC</LinearSequence>
                                        <StartingPosition>715</StartingPosition>
                                        <EndingPosition>731</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1387</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>715-731</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KTSVDCNMYICGDSTEC</LinearSequence>
                                        <StartingPosition>715</StartingPosition>
                                        <EndingPosition>731</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P104</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YICGDSTECANLLLQYG</LinearSequence>
                        <StartingPosition>723</StartingPosition>
                        <EndingPosition>739</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>74173</EpitopeId>
                <ReferenceStartingPosition>723</ReferenceStartingPosition>
                <ReferenceEndingPosition>739</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1388</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>723-739</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YICGDSTECANLLLQYG</LinearSequence>
                                        <StartingPosition>723</StartingPosition>
                                        <EndingPosition>739</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1389</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>723-739</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YICGDSTECANLLLQYG</LinearSequence>
                                        <StartingPosition>723</StartingPosition>
                                        <EndingPosition>739</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1390</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>723-739</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YICGDSTECANLLLQYG</LinearSequence>
                                        <StartingPosition>723</StartingPosition>
                                        <EndingPosition>739</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P105</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TECANLLLQYGSFCTQL</LinearSequence>
                        <StartingPosition>729</StartingPosition>
                        <EndingPosition>745</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>63309</EpitopeId>
                <ReferenceStartingPosition>729</ReferenceStartingPosition>
                <ReferenceEndingPosition>745</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1391</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>729-745</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TECANLLLQYGSFCTQL</LinearSequence>
                                        <StartingPosition>729</StartingPosition>
                                        <EndingPosition>745</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1392</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>729-745</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TECANLLLQYGSFCTQL</LinearSequence>
                                        <StartingPosition>729</StartingPosition>
                                        <EndingPosition>745</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1393</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>729-745</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TECANLLLQYGSFCTQL</LinearSequence>
                                        <StartingPosition>729</StartingPosition>
                                        <EndingPosition>745</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P106</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LQYGSFCTQLNRALSGI</LinearSequence>
                        <StartingPosition>736</StartingPosition>
                        <EndingPosition>752</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>39023</EpitopeId>
                <ReferenceStartingPosition>736</ReferenceStartingPosition>
                <ReferenceEndingPosition>752</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1396</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>28.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>736-752</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LQYGSFCTQLNRALSGI</LinearSequence>
                                        <StartingPosition>736</StartingPosition>
                                        <EndingPosition>752</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1397</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>736-752</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LQYGSFCTQLNRALSGI</LinearSequence>
                                        <StartingPosition>736</StartingPosition>
                                        <EndingPosition>752</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1398</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>736-752</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LQYGSFCTQLNRALSGI</LinearSequence>
                                        <StartingPosition>736</StartingPosition>
                                        <EndingPosition>752</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P107</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QLNRALSGIAAEQDRNT</LinearSequence>
                        <StartingPosition>744</StartingPosition>
                        <EndingPosition>760</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>51456</EpitopeId>
                <ReferenceStartingPosition>744</ReferenceStartingPosition>
                <ReferenceEndingPosition>760</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1401</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>744-760</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLNRALSGIAAEQDRNT</LinearSequence>
                                        <StartingPosition>744</StartingPosition>
                                        <EndingPosition>760</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1400</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>744-760</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLNRALSGIAAEQDRNT</LinearSequence>
                                        <StartingPosition>744</StartingPosition>
                                        <EndingPosition>760</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1399</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>744-760</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLNRALSGIAAEQDRNT</LinearSequence>
                                        <StartingPosition>744</StartingPosition>
                                        <EndingPosition>760</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P108</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IAAEQDRNTREVFAQVK</LinearSequence>
                        <StartingPosition>752</StartingPosition>
                        <EndingPosition>768</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>25219</EpitopeId>
                <ReferenceStartingPosition>752</ReferenceStartingPosition>
                <ReferenceEndingPosition>768</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1403</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>752-768</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAAEQDRNTREVFAQVK</LinearSequence>
                                        <StartingPosition>752</StartingPosition>
                                        <EndingPosition>768</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1404</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>752-768</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAAEQDRNTREVFAQVK</LinearSequence>
                                        <StartingPosition>752</StartingPosition>
                                        <EndingPosition>768</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1402</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>752-768</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAAEQDRNTREVFAQVK</LinearSequence>
                                        <StartingPosition>752</StartingPosition>
                                        <EndingPosition>768</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P109</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NTREVFAQVKQMYKTPT</LinearSequence>
                        <StartingPosition>759</StartingPosition>
                        <EndingPosition>775</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>46240</EpitopeId>
                <ReferenceStartingPosition>759</ReferenceStartingPosition>
                <ReferenceEndingPosition>775</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1406</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>759-775</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTREVFAQVKQMYKTPT</LinearSequence>
                                        <StartingPosition>759</StartingPosition>
                                        <EndingPosition>775</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1405</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>759-775</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTREVFAQVKQMYKTPT</LinearSequence>
                                        <StartingPosition>759</StartingPosition>
                                        <EndingPosition>775</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1407</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>759-775</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTREVFAQVKQMYKTPT</LinearSequence>
                                        <StartingPosition>759</StartingPosition>
                                        <EndingPosition>775</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P110</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VKQMYKTPTLKYFGGFN</LinearSequence>
                        <StartingPosition>767</StartingPosition>
                        <EndingPosition>783</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>69299</EpitopeId>
                <ReferenceStartingPosition>767</ReferenceStartingPosition>
                <ReferenceEndingPosition>783</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1409</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>767-783</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VKQMYKTPTLKYFGGFN</LinearSequence>
                                        <StartingPosition>767</StartingPosition>
                                        <EndingPosition>783</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1410</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>767-783</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VKQMYKTPTLKYFGGFN</LinearSequence>
                                        <StartingPosition>767</StartingPosition>
                                        <EndingPosition>783</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1408</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>7.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>767-783</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VKQMYKTPTLKYFGGFN</LinearSequence>
                                        <StartingPosition>767</StartingPosition>
                                        <EndingPosition>783</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P111</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TLKYFGGFNFSQILPDP</LinearSequence>
                        <StartingPosition>775</StartingPosition>
                        <EndingPosition>791</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>64888</EpitopeId>
                <ReferenceStartingPosition>775</ReferenceStartingPosition>
                <ReferenceEndingPosition>791</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1413</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>775-791</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLKYFGGFNFSQILPDP</LinearSequence>
                                        <StartingPosition>775</StartingPosition>
                                        <EndingPosition>791</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1412</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>775-791</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLKYFGGFNFSQILPDP</LinearSequence>
                                        <StartingPosition>775</StartingPosition>
                                        <EndingPosition>791</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1411</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>775-791</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLKYFGGFNFSQILPDP</LinearSequence>
                                        <StartingPosition>775</StartingPosition>
                                        <EndingPosition>791</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P112</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NFSQILPDPLKPTKRSF</LinearSequence>
                        <StartingPosition>783</StartingPosition>
                        <EndingPosition>799</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43924</EpitopeId>
                <ReferenceStartingPosition>783</ReferenceStartingPosition>
                <ReferenceEndingPosition>799</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1415</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>783-799</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFSQILPDPLKPTKRSF</LinearSequence>
                                        <StartingPosition>783</StartingPosition>
                                        <EndingPosition>799</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1416</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>783-799</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFSQILPDPLKPTKRSF</LinearSequence>
                                        <StartingPosition>783</StartingPosition>
                                        <EndingPosition>799</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1414</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>783-799</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFSQILPDPLKPTKRSF</LinearSequence>
                                        <StartingPosition>783</StartingPosition>
                                        <EndingPosition>799</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P113</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PLKPTKRSFIEDLLFNK</LinearSequence>
                        <StartingPosition>791</StartingPosition>
                        <EndingPosition>807</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>48383</EpitopeId>
                <ReferenceStartingPosition>791</ReferenceStartingPosition>
                <ReferenceEndingPosition>807</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1418</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>791-807</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PLKPTKRSFIEDLLFNK</LinearSequence>
                                        <StartingPosition>791</StartingPosition>
                                        <EndingPosition>807</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1419</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>791-807</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PLKPTKRSFIEDLLFNK</LinearSequence>
                                        <StartingPosition>791</StartingPosition>
                                        <EndingPosition>807</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1417</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>791-807</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PLKPTKRSFIEDLLFNK</LinearSequence>
                                        <StartingPosition>791</StartingPosition>
                                        <EndingPosition>807</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P114</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FIEDLLFNKVTLADAGF</LinearSequence>
                        <StartingPosition>799</StartingPosition>
                        <EndingPosition>815</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>16183</EpitopeId>
                <ReferenceStartingPosition>799</ReferenceStartingPosition>
                <ReferenceEndingPosition>815</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1421</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>799-815</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FIEDLLFNKVTLADAGF</LinearSequence>
                                        <StartingPosition>799</StartingPosition>
                                        <EndingPosition>815</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1422</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>799-815</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FIEDLLFNKVTLADAGF</LinearSequence>
                                        <StartingPosition>799</StartingPosition>
                                        <EndingPosition>815</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1420</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>799-815</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FIEDLLFNKVTLADAGF</LinearSequence>
                                        <StartingPosition>799</StartingPosition>
                                        <EndingPosition>815</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P115</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KVTLADAGFMKQYGECL</LinearSequence>
                        <StartingPosition>807</StartingPosition>
                        <EndingPosition>823</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>34217</EpitopeId>
                <ReferenceStartingPosition>807</ReferenceStartingPosition>
                <ReferenceEndingPosition>823</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1424</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>807-823</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KVTLADAGFMKQYGECL</LinearSequence>
                                        <StartingPosition>807</StartingPosition>
                                        <EndingPosition>823</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1425</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>807-823</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KVTLADAGFMKQYGECL</LinearSequence>
                                        <StartingPosition>807</StartingPosition>
                                        <EndingPosition>823</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1423</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>807-823</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KVTLADAGFMKQYGECL</LinearSequence>
                                        <StartingPosition>807</StartingPosition>
                                        <EndingPosition>823</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P116</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GFMKQYGECLGDINARD</LinearSequence>
                        <StartingPosition>814</StartingPosition>
                        <EndingPosition>830</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>19585</EpitopeId>
                <ReferenceStartingPosition>814</ReferenceStartingPosition>
                <ReferenceEndingPosition>830</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1427</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>814-830</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GFMKQYGECLGDINARD</LinearSequence>
                                        <StartingPosition>814</StartingPosition>
                                        <EndingPosition>830</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1426</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>28.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>814-830</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GFMKQYGECLGDINARD</LinearSequence>
                                        <StartingPosition>814</StartingPosition>
                                        <EndingPosition>830</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1428</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>814-830</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GFMKQYGECLGDINARD</LinearSequence>
                                        <StartingPosition>814</StartingPosition>
                                        <EndingPosition>830</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P117</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CLGDINARDLICAQKFN</LinearSequence>
                        <StartingPosition>822</StartingPosition>
                        <EndingPosition>838</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>6562</EpitopeId>
                <ReferenceStartingPosition>822</ReferenceStartingPosition>
                <ReferenceEndingPosition>838</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1429</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>822-838</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CLGDINARDLICAQKFN</LinearSequence>
                                        <StartingPosition>822</StartingPosition>
                                        <EndingPosition>838</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1431</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>822-838</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CLGDINARDLICAQKFN</LinearSequence>
                                        <StartingPosition>822</StartingPosition>
                                        <EndingPosition>838</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1430</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>822-838</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CLGDINARDLICAQKFN</LinearSequence>
                                        <StartingPosition>822</StartingPosition>
                                        <EndingPosition>838</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P118</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ARDLICAQKFNGLTVLP</LinearSequence>
                        <StartingPosition>828</StartingPosition>
                        <EndingPosition>844</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>4129</EpitopeId>
                <ReferenceStartingPosition>828</ReferenceStartingPosition>
                <ReferenceEndingPosition>844</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1434</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>828-844</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ARDLICAQKFNGLTVLP</LinearSequence>
                                        <StartingPosition>828</StartingPosition>
                                        <EndingPosition>844</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1433</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>828-844</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ARDLICAQKFNGLTVLP</LinearSequence>
                                        <StartingPosition>828</StartingPosition>
                                        <EndingPosition>844</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1432</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>828-844</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ARDLICAQKFNGLTVLP</LinearSequence>
                                        <StartingPosition>828</StartingPosition>
                                        <EndingPosition>844</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P119</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AQKFNGLTVLPPLLTDD</LinearSequence>
                        <StartingPosition>834</StartingPosition>
                        <EndingPosition>850</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>3983</EpitopeId>
                <ReferenceStartingPosition>834</ReferenceStartingPosition>
                <ReferenceEndingPosition>850</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1437</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>834-850</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AQKFNGLTVLPPLLTDD</LinearSequence>
                                        <StartingPosition>834</StartingPosition>
                                        <EndingPosition>850</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1435</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>834-850</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AQKFNGLTVLPPLLTDD</LinearSequence>
                                        <StartingPosition>834</StartingPosition>
                                        <EndingPosition>850</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1436</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>834-850</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AQKFNGLTVLPPLLTDD</LinearSequence>
                                        <StartingPosition>834</StartingPosition>
                                        <EndingPosition>850</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P120</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VLPPLLTDDMIAAYTAA</LinearSequence>
                        <StartingPosition>842</StartingPosition>
                        <EndingPosition>858</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>69699</EpitopeId>
                <ReferenceStartingPosition>842</ReferenceStartingPosition>
                <ReferenceEndingPosition>858</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1440</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>842-858</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLPPLLTDDMIAAYTAA</LinearSequence>
                                        <StartingPosition>842</StartingPosition>
                                        <EndingPosition>858</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1439</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>842-858</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLPPLLTDDMIAAYTAA</LinearSequence>
                                        <StartingPosition>842</StartingPosition>
                                        <EndingPosition>858</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1438</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>19</NumberOfSubjectsResponded>
                            <ResponseFrequency>45.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>842-858</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLPPLLTDDMIAAYTAA</LinearSequence>
                                        <StartingPosition>842</StartingPosition>
                                        <EndingPosition>858</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P121</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DMIAAYTAALVSGTATA</LinearSequence>
                        <StartingPosition>850</StartingPosition>
                        <EndingPosition>866</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>9365</EpitopeId>
                <ReferenceStartingPosition>850</ReferenceStartingPosition>
                <ReferenceEndingPosition>866</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1443</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>850-866</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DMIAAYTAALVSGTATA</LinearSequence>
                                        <StartingPosition>850</StartingPosition>
                                        <EndingPosition>866</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1442</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>850-866</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DMIAAYTAALVSGTATA</LinearSequence>
                                        <StartingPosition>850</StartingPosition>
                                        <EndingPosition>866</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1441</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>18</NumberOfSubjectsResponded>
                            <ResponseFrequency>42.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>850-866</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DMIAAYTAALVSGTATA</LinearSequence>
                                        <StartingPosition>850</StartingPosition>
                                        <EndingPosition>866</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P122</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AALVSGTATAGWTFGAG</LinearSequence>
                        <StartingPosition>857</StartingPosition>
                        <EndingPosition>873</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>307</EpitopeId>
                <ReferenceStartingPosition>857</ReferenceStartingPosition>
                <ReferenceEndingPosition>873</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1445</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>857-873</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AALVSGTATAGWTFGAG</LinearSequence>
                                        <StartingPosition>857</StartingPosition>
                                        <EndingPosition>873</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1444</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>18</NumberOfSubjectsResponded>
                            <ResponseFrequency>42.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>857-873</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AALVSGTATAGWTFGAG</LinearSequence>
                                        <StartingPosition>857</StartingPosition>
                                        <EndingPosition>873</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1446</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>857-873</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AALVSGTATAGWTFGAG</LinearSequence>
                                        <StartingPosition>857</StartingPosition>
                                        <EndingPosition>873</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P123</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TAGWTFGAGAALQIPFA</LinearSequence>
                        <StartingPosition>865</StartingPosition>
                        <EndingPosition>881</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>62872</EpitopeId>
                <ReferenceStartingPosition>865</ReferenceStartingPosition>
                <ReferenceEndingPosition>881</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1449</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>865-881</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TAGWTFGAGAALQIPFA</LinearSequence>
                                        <StartingPosition>865</StartingPosition>
                                        <EndingPosition>881</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1448</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>865-881</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TAGWTFGAGAALQIPFA</LinearSequence>
                                        <StartingPosition>865</StartingPosition>
                                        <EndingPosition>881</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1447</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>23</NumberOfSubjectsResponded>
                            <ResponseFrequency>54.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>865-881</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TAGWTFGAGAALQIPFA</LinearSequence>
                                        <StartingPosition>865</StartingPosition>
                                        <EndingPosition>881</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P124</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GAALQIPFAMQMAYRFN</LinearSequence>
                        <StartingPosition>873</StartingPosition>
                        <EndingPosition>889</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>18515</EpitopeId>
                <ReferenceStartingPosition>873</ReferenceStartingPosition>
                <ReferenceEndingPosition>889</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1451</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>873-889</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAALQIPFAMQMAYRFN</LinearSequence>
                                        <StartingPosition>873</StartingPosition>
                                        <EndingPosition>889</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1452</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>873-889</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAALQIPFAMQMAYRFN</LinearSequence>
                                        <StartingPosition>873</StartingPosition>
                                        <EndingPosition>889</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1450</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>47.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>873-889</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAALQIPFAMQMAYRFN</LinearSequence>
                                        <StartingPosition>873</StartingPosition>
                                        <EndingPosition>889</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P125</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PFAMQMAYRFNGIGVTQ</LinearSequence>
                        <StartingPosition>879</StartingPosition>
                        <EndingPosition>895</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>47479</EpitopeId>
                <ReferenceStartingPosition>879</ReferenceStartingPosition>
                <ReferenceEndingPosition>895</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1454</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>879-895</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PFAMQMAYRFNGIGVTQ</LinearSequence>
                                        <StartingPosition>879</StartingPosition>
                                        <EndingPosition>895</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1455</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>879-895</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PFAMQMAYRFNGIGVTQ</LinearSequence>
                                        <StartingPosition>879</StartingPosition>
                                        <EndingPosition>895</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1453</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>24</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>879-895</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PFAMQMAYRFNGIGVTQ</LinearSequence>
                                        <StartingPosition>879</StartingPosition>
                                        <EndingPosition>895</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P126</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MAYRFNGIGVTQNVLYE</LinearSequence>
                        <StartingPosition>884</StartingPosition>
                        <EndingPosition>900</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>41177</EpitopeId>
                <ReferenceStartingPosition>884</ReferenceStartingPosition>
                <ReferenceEndingPosition>900</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1457</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>884-900</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MAYRFNGIGVTQNVLYE</LinearSequence>
                                        <StartingPosition>884</StartingPosition>
                                        <EndingPosition>900</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1458</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>884-900</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MAYRFNGIGVTQNVLYE</LinearSequence>
                                        <StartingPosition>884</StartingPosition>
                                        <EndingPosition>900</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1456</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>24</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>884-900</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MAYRFNGIGVTQNVLYE</LinearSequence>
                                        <StartingPosition>884</StartingPosition>
                                        <EndingPosition>900</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P127</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GIGVTQNVLYENQKQIA</LinearSequence>
                        <StartingPosition>890</StartingPosition>
                        <EndingPosition>906</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>20288</EpitopeId>
                <ReferenceStartingPosition>890</ReferenceStartingPosition>
                <ReferenceEndingPosition>906</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1460</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>890-906</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GIGVTQNVLYENQKQIA</LinearSequence>
                                        <StartingPosition>890</StartingPosition>
                                        <EndingPosition>906</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1461</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>890-906</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GIGVTQNVLYENQKQIA</LinearSequence>
                                        <StartingPosition>890</StartingPosition>
                                        <EndingPosition>906</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1459</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>23</NumberOfSubjectsResponded>
                            <ResponseFrequency>54.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>890-906</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GIGVTQNVLYENQKQIA</LinearSequence>
                                        <StartingPosition>890</StartingPosition>
                                        <EndingPosition>906</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P128</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VLYENQKQIANQFNKAI</LinearSequence>
                        <StartingPosition>897</StartingPosition>
                        <EndingPosition>913</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>69865</EpitopeId>
                <ReferenceStartingPosition>897</ReferenceStartingPosition>
                <ReferenceEndingPosition>913</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1463</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>897-913</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLYENQKQIANQFNKAI</LinearSequence>
                                        <StartingPosition>897</StartingPosition>
                                        <EndingPosition>913</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1464</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>897-913</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLYENQKQIANQFNKAI</LinearSequence>
                                        <StartingPosition>897</StartingPosition>
                                        <EndingPosition>913</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1462</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>47.6</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate. This peptide is located at one of the 5 immunodominant sites.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>897-913</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLYENQKQIANQFNKAI</LinearSequence>
                                        <StartingPosition>897</StartingPosition>
                                        <EndingPosition>913</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P129</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QIANQFNKAISQIQESL</LinearSequence>
                        <StartingPosition>904</StartingPosition>
                        <EndingPosition>920</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>51043</EpitopeId>
                <ReferenceStartingPosition>904</ReferenceStartingPosition>
                <ReferenceEndingPosition>920</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1465</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.9</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>904-920</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QIANQFNKAISQIQESL</LinearSequence>
                                        <StartingPosition>904</StartingPosition>
                                        <EndingPosition>920</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1467</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>904-920</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QIANQFNKAISQIQESL</LinearSequence>
                                        <StartingPosition>904</StartingPosition>
                                        <EndingPosition>920</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1466</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>904-920</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QIANQFNKAISQIQESL</LinearSequence>
                                        <StartingPosition>904</StartingPosition>
                                        <EndingPosition>920</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P130</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAISQIQESLTTTSTAL</LinearSequence>
                        <StartingPosition>911</StartingPosition>
                        <EndingPosition>927</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>29832</EpitopeId>
                <ReferenceStartingPosition>911</ReferenceStartingPosition>
                <ReferenceEndingPosition>927</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1468</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>911-927</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAISQIQESLTTTSTAL</LinearSequence>
                                        <StartingPosition>911</StartingPosition>
                                        <EndingPosition>927</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1469</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>911-927</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAISQIQESLTTTSTAL</LinearSequence>
                                        <StartingPosition>911</StartingPosition>
                                        <EndingPosition>927</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1470</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>911-927</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAISQIQESLTTTSTAL</LinearSequence>
                                        <StartingPosition>911</StartingPosition>
                                        <EndingPosition>927</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P131</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ESLTTTSTALGKLQDVV</LinearSequence>
                        <StartingPosition>918</StartingPosition>
                        <EndingPosition>934</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>14208</EpitopeId>
                <ReferenceStartingPosition>918</ReferenceStartingPosition>
                <ReferenceEndingPosition>934</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1472</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>918-934</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ESLTTTSTALGKLQDVV</LinearSequence>
                                        <StartingPosition>918</StartingPosition>
                                        <EndingPosition>934</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1471</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>918-934</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ESLTTTSTALGKLQDVV</LinearSequence>
                                        <StartingPosition>918</StartingPosition>
                                        <EndingPosition>934</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1473</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>918-934</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ESLTTTSTALGKLQDVV</LinearSequence>
                                        <StartingPosition>918</StartingPosition>
                                        <EndingPosition>934</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P132</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TALGKLQDVVNQNAQAL</LinearSequence>
                        <StartingPosition>925</StartingPosition>
                        <EndingPosition>941</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>62908</EpitopeId>
                <ReferenceStartingPosition>925</ReferenceStartingPosition>
                <ReferenceEndingPosition>941</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1475</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>925-941</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TALGKLQDVVNQNAQAL</LinearSequence>
                                        <StartingPosition>925</StartingPosition>
                                        <EndingPosition>941</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1474</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>925-941</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TALGKLQDVVNQNAQAL</LinearSequence>
                                        <StartingPosition>925</StartingPosition>
                                        <EndingPosition>941</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1476</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>925-941</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TALGKLQDVVNQNAQAL</LinearSequence>
                                        <StartingPosition>925</StartingPosition>
                                        <EndingPosition>941</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P133</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DVVNQNAQALNTLVKQL</LinearSequence>
                        <StartingPosition>932</StartingPosition>
                        <EndingPosition>948</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>10778</EpitopeId>
                <ReferenceStartingPosition>932</ReferenceStartingPosition>
                <ReferenceEndingPosition>948</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1479</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>932-948</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DVVNQNAQALNTLVKQL</LinearSequence>
                                        <StartingPosition>932</StartingPosition>
                                        <EndingPosition>948</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1478</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>932-948</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DVVNQNAQALNTLVKQL</LinearSequence>
                                        <StartingPosition>932</StartingPosition>
                                        <EndingPosition>948</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1477</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>9</NumberOfSubjectsResponded>
                            <ResponseFrequency>21.4</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>932-948</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DVVNQNAQALNTLVKQL</LinearSequence>
                                        <StartingPosition>932</StartingPosition>
                                        <EndingPosition>948</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P134</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QALNTLVKQLSSNFGAI</LinearSequence>
                        <StartingPosition>939</StartingPosition>
                        <EndingPosition>955</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>50311</EpitopeId>
                <ReferenceStartingPosition>939</ReferenceStartingPosition>
                <ReferenceEndingPosition>955</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1481</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>939-955</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QALNTLVKQLSSNFGAI</LinearSequence>
                                        <StartingPosition>939</StartingPosition>
                                        <EndingPosition>955</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1482</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>939-955</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QALNTLVKQLSSNFGAI</LinearSequence>
                                        <StartingPosition>939</StartingPosition>
                                        <EndingPosition>955</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1480</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>16</NumberOfSubjectsResponded>
                            <ResponseFrequency>38.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>939-955</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QALNTLVKQLSSNFGAI</LinearSequence>
                                        <StartingPosition>939</StartingPosition>
                                        <EndingPosition>955</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P135</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KQLSSNFGAISSVLNDI</LinearSequence>
                        <StartingPosition>946</StartingPosition>
                        <EndingPosition>962</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>33032</EpitopeId>
                <ReferenceStartingPosition>946</ReferenceStartingPosition>
                <ReferenceEndingPosition>962</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1484</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>946-962</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KQLSSNFGAISSVLNDI</LinearSequence>
                                        <StartingPosition>946</StartingPosition>
                                        <EndingPosition>962</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1483</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>946-962</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KQLSSNFGAISSVLNDI</LinearSequence>
                                        <StartingPosition>946</StartingPosition>
                                        <EndingPosition>962</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1485</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>946-962</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KQLSSNFGAISSVLNDI</LinearSequence>
                                        <StartingPosition>946</StartingPosition>
                                        <EndingPosition>962</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P136</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AISSVLNDILSRLDKVE</LinearSequence>
                        <StartingPosition>954</StartingPosition>
                        <EndingPosition>970</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>2092</EpitopeId>
                <ReferenceStartingPosition>954</ReferenceStartingPosition>
                <ReferenceEndingPosition>970</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1487</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>954-970</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AISSVLNDILSRLDKVE</LinearSequence>
                                        <StartingPosition>954</StartingPosition>
                                        <EndingPosition>970</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1486</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>954-970</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AISSVLNDILSRLDKVE</LinearSequence>
                                        <StartingPosition>954</StartingPosition>
                                        <EndingPosition>970</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1488</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>954-970</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AISSVLNDILSRLDKVE</LinearSequence>
                                        <StartingPosition>954</StartingPosition>
                                        <EndingPosition>970</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P137</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ILSRLDKVEAEVQIDRL</LinearSequence>
                        <StartingPosition>962</StartingPosition>
                        <EndingPosition>978</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>27357</EpitopeId>
                <ReferenceStartingPosition>962</ReferenceStartingPosition>
                <ReferenceEndingPosition>978</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1490</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>962-978</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ILSRLDKVEAEVQIDRL</LinearSequence>
                                        <StartingPosition>962</StartingPosition>
                                        <EndingPosition>978</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1491</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>962-978</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ILSRLDKVEAEVQIDRL</LinearSequence>
                                        <StartingPosition>962</StartingPosition>
                                        <EndingPosition>978</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1489</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>962-978</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ILSRLDKVEAEVQIDRL</LinearSequence>
                                        <StartingPosition>962</StartingPosition>
                                        <EndingPosition>978</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P138</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EAEVQIDRLITGRLQSL</LinearSequence>
                        <StartingPosition>970</StartingPosition>
                        <EndingPosition>986</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>11038</EpitopeId>
                <ReferenceStartingPosition>970</ReferenceStartingPosition>
                <ReferenceEndingPosition>986</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1493</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>970-986</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EAEVQIDRLITGRLQSL</LinearSequence>
                                        <StartingPosition>970</StartingPosition>
                                        <EndingPosition>986</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1494</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>970-986</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EAEVQIDRLITGRLQSL</LinearSequence>
                                        <StartingPosition>970</StartingPosition>
                                        <EndingPosition>986</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1492</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>970-986</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EAEVQIDRLITGRLQSL</LinearSequence>
                                        <StartingPosition>970</StartingPosition>
                                        <EndingPosition>986</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P139</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RLITGRLQSLQTYVTQQ</LinearSequence>
                        <StartingPosition>977</StartingPosition>
                        <EndingPosition>993</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>54599</EpitopeId>
                <ReferenceStartingPosition>977</ReferenceStartingPosition>
                <ReferenceEndingPosition>993</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1495</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>19</NumberOfSubjectsResponded>
                            <ResponseFrequency>45.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>977-993</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RLITGRLQSLQTYVTQQ</LinearSequence>
                                        <StartingPosition>977</StartingPosition>
                                        <EndingPosition>993</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1496</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>977-993</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RLITGRLQSLQTYVTQQ</LinearSequence>
                                        <StartingPosition>977</StartingPosition>
                                        <EndingPosition>993</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1497</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>977-993</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RLITGRLQSLQTYVTQQ</LinearSequence>
                                        <StartingPosition>977</StartingPosition>
                                        <EndingPosition>993</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P140</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SLQTYVTQQLIRAAEIR</LinearSequence>
                        <StartingPosition>985</StartingPosition>
                        <EndingPosition>1001</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>59425</EpitopeId>
                <ReferenceStartingPosition>985</ReferenceStartingPosition>
                <ReferenceEndingPosition>1001</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1500</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>985-1001</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLQTYVTQQLIRAAEIR</LinearSequence>
                                        <StartingPosition>985</StartingPosition>
                                        <EndingPosition>1001</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1498</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>16</NumberOfSubjectsResponded>
                            <ResponseFrequency>38.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>985-1001</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLQTYVTQQLIRAAEIR</LinearSequence>
                                        <StartingPosition>985</StartingPosition>
                                        <EndingPosition>1001</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1499</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>985-1001</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLQTYVTQQLIRAAEIR</LinearSequence>
                                        <StartingPosition>985</StartingPosition>
                                        <EndingPosition>1001</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P141</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QLIRAAEIRASANLAAT</LinearSequence>
                        <StartingPosition>993</StartingPosition>
                        <EndingPosition>1009</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>51379</EpitopeId>
                <ReferenceStartingPosition>993</ReferenceStartingPosition>
                <ReferenceEndingPosition>1009</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1502</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>993-1009</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLIRAAEIRASANLAAT</LinearSequence>
                                        <StartingPosition>993</StartingPosition>
                                        <EndingPosition>1009</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1503</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>993-1009</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLIRAAEIRASANLAAT</LinearSequence>
                                        <StartingPosition>993</StartingPosition>
                                        <EndingPosition>1009</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1501</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>993-1009</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QLIRAAEIRASANLAAT</LinearSequence>
                                        <StartingPosition>993</StartingPosition>
                                        <EndingPosition>1009</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P142</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RASANLAATKMSECVLG</LinearSequence>
                        <StartingPosition>1001</StartingPosition>
                        <EndingPosition>1017</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>53202</EpitopeId>
                <ReferenceStartingPosition>1001</ReferenceStartingPosition>
                <ReferenceEndingPosition>1017</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1505</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1001-1017</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RASANLAATKMSECVLG</LinearSequence>
                                        <StartingPosition>1001</StartingPosition>
                                        <EndingPosition>1017</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1506</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1001-1017</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RASANLAATKMSECVLG</LinearSequence>
                                        <StartingPosition>1001</StartingPosition>
                                        <EndingPosition>1017</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1504</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1001-1017</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RASANLAATKMSECVLG</LinearSequence>
                                        <StartingPosition>1001</StartingPosition>
                                        <EndingPosition>1017</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P143</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AATKMSECVLGQSKRVD</LinearSequence>
                        <StartingPosition>1007</StartingPosition>
                        <EndingPosition>1023</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>462</EpitopeId>
                <ReferenceStartingPosition>1007</ReferenceStartingPosition>
                <ReferenceEndingPosition>1023</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1507</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1007-1023</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AATKMSECVLGQSKRVD</LinearSequence>
                                        <StartingPosition>1007</StartingPosition>
                                        <EndingPosition>1023</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1508</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1007-1023</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AATKMSECVLGQSKRVD</LinearSequence>
                                        <StartingPosition>1007</StartingPosition>
                                        <EndingPosition>1023</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1509</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1007-1023</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AATKMSECVLGQSKRVD</LinearSequence>
                                        <StartingPosition>1007</StartingPosition>
                                        <EndingPosition>1023</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P144</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VLGQSKRVDFCGKGYHL</LinearSequence>
                        <StartingPosition>1015</StartingPosition>
                        <EndingPosition>1031</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>69513</EpitopeId>
                <ReferenceStartingPosition>1015</ReferenceStartingPosition>
                <ReferenceEndingPosition>1031</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1511</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1015-1031</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLGQSKRVDFCGKGYHL</LinearSequence>
                                        <StartingPosition>1015</StartingPosition>
                                        <EndingPosition>1031</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1512</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1015-1031</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLGQSKRVDFCGKGYHL</LinearSequence>
                                        <StartingPosition>1015</StartingPosition>
                                        <EndingPosition>1031</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1510</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1015-1031</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VLGQSKRVDFCGKGYHL</LinearSequence>
                                        <StartingPosition>1015</StartingPosition>
                                        <EndingPosition>1031</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P145</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DFCGKGYHLMSFPQAAP</LinearSequence>
                        <StartingPosition>1023</StartingPosition>
                        <EndingPosition>1039</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>8239</EpitopeId>
                <ReferenceStartingPosition>1023</ReferenceStartingPosition>
                <ReferenceEndingPosition>1039</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1514</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1023-1039</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DFCGKGYHLMSFPQAAP</LinearSequence>
                                        <StartingPosition>1023</StartingPosition>
                                        <EndingPosition>1039</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1513</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1023-1039</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DFCGKGYHLMSFPQAAP</LinearSequence>
                                        <StartingPosition>1023</StartingPosition>
                                        <EndingPosition>1039</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1515</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1023-1039</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DFCGKGYHLMSFPQAAP</LinearSequence>
                                        <StartingPosition>1023</StartingPosition>
                                        <EndingPosition>1039</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P146</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LMSFPQAAPHGVVFLHV</LinearSequence>
                        <StartingPosition>1031</StartingPosition>
                        <EndingPosition>1047</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>38118</EpitopeId>
                <ReferenceStartingPosition>1031</ReferenceStartingPosition>
                <ReferenceEndingPosition>1047</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1516</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>31</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1031-1047</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LMSFPQAAPHGVVFLHV</LinearSequence>
                                        <StartingPosition>1031</StartingPosition>
                                        <EndingPosition>1047</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1518</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1031-1047</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LMSFPQAAPHGVVFLHV</LinearSequence>
                                        <StartingPosition>1031</StartingPosition>
                                        <EndingPosition>1047</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1517</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1031-1047</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LMSFPQAAPHGVVFLHV</LinearSequence>
                                        <StartingPosition>1031</StartingPosition>
                                        <EndingPosition>1047</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P147</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PHGVVFLHVTYVPSQER</LinearSequence>
                        <StartingPosition>1039</StartingPosition>
                        <EndingPosition>1055</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>47823</EpitopeId>
                <ReferenceStartingPosition>1039</ReferenceStartingPosition>
                <ReferenceEndingPosition>1055</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1520</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1039-1055</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PHGVVFLHVTYVPSQER</LinearSequence>
                                        <StartingPosition>1039</StartingPosition>
                                        <EndingPosition>1055</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1519</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>11</NumberOfSubjectsResponded>
                            <ResponseFrequency>26.2</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1039-1055</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PHGVVFLHVTYVPSQER</LinearSequence>
                                        <StartingPosition>1039</StartingPosition>
                                        <EndingPosition>1055</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1521</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1039-1055</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PHGVVFLHVTYVPSQER</LinearSequence>
                                        <StartingPosition>1039</StartingPosition>
                                        <EndingPosition>1055</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P148</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VTYVPSQERNFTTAPAI</LinearSequence>
                        <StartingPosition>1047</StartingPosition>
                        <EndingPosition>1063</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>71589</EpitopeId>
                <ReferenceStartingPosition>1047</ReferenceStartingPosition>
                <ReferenceEndingPosition>1063</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1523</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1047-1063</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTYVPSQERNFTTAPAI</LinearSequence>
                                        <StartingPosition>1047</StartingPosition>
                                        <EndingPosition>1063</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1522</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>23.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1047-1063</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTYVPSQERNFTTAPAI</LinearSequence>
                                        <StartingPosition>1047</StartingPosition>
                                        <EndingPosition>1063</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1524</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1047-1063</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTYVPSQERNFTTAPAI</LinearSequence>
                                        <StartingPosition>1047</StartingPosition>
                                        <EndingPosition>1063</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P149</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RNFTTAPAICHEGKAYF</LinearSequence>
                        <StartingPosition>1055</StartingPosition>
                        <EndingPosition>1071</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>54989</EpitopeId>
                <ReferenceStartingPosition>1055</ReferenceStartingPosition>
                <ReferenceEndingPosition>1071</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1525</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>7</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1055-1071</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNFTTAPAICHEGKAYF</LinearSequence>
                                        <StartingPosition>1055</StartingPosition>
                                        <EndingPosition>1071</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1526</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1055-1071</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNFTTAPAICHEGKAYF</LinearSequence>
                                        <StartingPosition>1055</StartingPosition>
                                        <EndingPosition>1071</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1527</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1055-1071</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RNFTTAPAICHEGKAYF</LinearSequence>
                                        <StartingPosition>1055</StartingPosition>
                                        <EndingPosition>1071</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P150</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AICHEGKAYFPREGVFV</LinearSequence>
                        <StartingPosition>1062</StartingPosition>
                        <EndingPosition>1078</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>1860</EpitopeId>
                <ReferenceStartingPosition>1062</ReferenceStartingPosition>
                <ReferenceEndingPosition>1078</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1528</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1062-1078</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AICHEGKAYFPREGVFV</LinearSequence>
                                        <StartingPosition>1062</StartingPosition>
                                        <EndingPosition>1078</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1530</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1062-1078</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AICHEGKAYFPREGVFV</LinearSequence>
                                        <StartingPosition>1062</StartingPosition>
                                        <EndingPosition>1078</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1529</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1062-1078</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AICHEGKAYFPREGVFV</LinearSequence>
                                        <StartingPosition>1062</StartingPosition>
                                        <EndingPosition>1078</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P151</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AYFPREGVFVFNGTSWF</LinearSequence>
                        <StartingPosition>1069</StartingPosition>
                        <EndingPosition>1085</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>5773</EpitopeId>
                <ReferenceStartingPosition>1069</ReferenceStartingPosition>
                <ReferenceEndingPosition>1085</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1531</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>4.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1069-1085</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AYFPREGVFVFNGTSWF</LinearSequence>
                                        <StartingPosition>1069</StartingPosition>
                                        <EndingPosition>1085</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1533</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1069-1085</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AYFPREGVFVFNGTSWF</LinearSequence>
                                        <StartingPosition>1069</StartingPosition>
                                        <EndingPosition>1085</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1532</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1069-1085</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AYFPREGVFVFNGTSWF</LinearSequence>
                                        <StartingPosition>1069</StartingPosition>
                                        <EndingPosition>1085</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P152</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FVFNGTSWFITQRNFFS</LinearSequence>
                        <StartingPosition>1077</StartingPosition>
                        <EndingPosition>1093</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>18161</EpitopeId>
                <ReferenceStartingPosition>1077</ReferenceStartingPosition>
                <ReferenceEndingPosition>1093</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1534</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>4.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1077-1093</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FVFNGTSWFITQRNFFS</LinearSequence>
                                        <StartingPosition>1077</StartingPosition>
                                        <EndingPosition>1093</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1536</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1077-1093</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FVFNGTSWFITQRNFFS</LinearSequence>
                                        <StartingPosition>1077</StartingPosition>
                                        <EndingPosition>1093</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1535</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1077-1093</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FVFNGTSWFITQRNFFS</LinearSequence>
                                        <StartingPosition>1077</StartingPosition>
                                        <EndingPosition>1093</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P153</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SWFITQRNFFSPQIITT</LinearSequence>
                        <StartingPosition>1083</StartingPosition>
                        <EndingPosition>1099</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>62443</EpitopeId>
                <ReferenceStartingPosition>1083</ReferenceStartingPosition>
                <ReferenceEndingPosition>1099</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1539</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1083-1099</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SWFITQRNFFSPQIITT</LinearSequence>
                                        <StartingPosition>1083</StartingPosition>
                                        <EndingPosition>1099</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1538</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1083-1099</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SWFITQRNFFSPQIITT</LinearSequence>
                                        <StartingPosition>1083</StartingPosition>
                                        <EndingPosition>1099</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1537</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1083-1099</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SWFITQRNFFSPQIITT</LinearSequence>
                                        <StartingPosition>1083</StartingPosition>
                                        <EndingPosition>1099</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P154</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NFFSPQIITTDNTFVSG</LinearSequence>
                        <StartingPosition>1090</StartingPosition>
                        <EndingPosition>1106</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43834</EpitopeId>
                <ReferenceStartingPosition>1090</ReferenceStartingPosition>
                <ReferenceEndingPosition>1106</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1540</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1090-1106</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFFSPQIITTDNTFVSG</LinearSequence>
                                        <StartingPosition>1090</StartingPosition>
                                        <EndingPosition>1106</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1542</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1090-1106</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFFSPQIITTDNTFVSG</LinearSequence>
                                        <StartingPosition>1090</StartingPosition>
                                        <EndingPosition>1106</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1541</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1090-1106</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NFFSPQIITTDNTFVSG</LinearSequence>
                                        <StartingPosition>1090</StartingPosition>
                                        <EndingPosition>1106</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P155</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ITTDNTFVSGNCDVVIG</LinearSequence>
                        <StartingPosition>1097</StartingPosition>
                        <EndingPosition>1113</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>29108</EpitopeId>
                <ReferenceStartingPosition>1097</ReferenceStartingPosition>
                <ReferenceEndingPosition>1113</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1543</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1097-1113</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ITTDNTFVSGNCDVVIG</LinearSequence>
                                        <StartingPosition>1097</StartingPosition>
                                        <EndingPosition>1113</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1545</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1097-1113</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ITTDNTFVSGNCDVVIG</LinearSequence>
                                        <StartingPosition>1097</StartingPosition>
                                        <EndingPosition>1113</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1544</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1097-1113</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ITTDNTFVSGNCDVVIG</LinearSequence>
                                        <StartingPosition>1097</StartingPosition>
                                        <EndingPosition>1113</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P156</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGNCDVVIGIINNTVYD</LinearSequence>
                        <StartingPosition>1105</StartingPosition>
                        <EndingPosition>1121</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>58143</EpitopeId>
                <ReferenceStartingPosition>1105</ReferenceStartingPosition>
                <ReferenceEndingPosition>1121</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1547</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1105-1121</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGNCDVVIGIINNTVYD</LinearSequence>
                                        <StartingPosition>1105</StartingPosition>
                                        <EndingPosition>1121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1546</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1105-1121</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGNCDVVIGIINNTVYD</LinearSequence>
                                        <StartingPosition>1105</StartingPosition>
                                        <EndingPosition>1121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1548</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1105-1121</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGNCDVVIGIINNTVYD</LinearSequence>
                                        <StartingPosition>1105</StartingPosition>
                                        <EndingPosition>1121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P157</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VIGIINNTVYDPLQPEL</LinearSequence>
                        <StartingPosition>1111</StartingPosition>
                        <EndingPosition>1127</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>68971</EpitopeId>
                <ReferenceStartingPosition>1111</ReferenceStartingPosition>
                <ReferenceEndingPosition>1127</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1550</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1111-1127</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VIGIINNTVYDPLQPEL</LinearSequence>
                                        <StartingPosition>1111</StartingPosition>
                                        <EndingPosition>1127</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1549</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1111-1127</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VIGIINNTVYDPLQPEL</LinearSequence>
                                        <StartingPosition>1111</StartingPosition>
                                        <EndingPosition>1127</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1551</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1111-1127</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VIGIINNTVYDPLQPEL</LinearSequence>
                                        <StartingPosition>1111</StartingPosition>
                                        <EndingPosition>1127</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P158</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TVYDPLQPELDSFKEEL</LinearSequence>
                        <StartingPosition>1118</StartingPosition>
                        <EndingPosition>1134</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>67220</EpitopeId>
                <ReferenceStartingPosition>1118</ReferenceStartingPosition>
                <ReferenceEndingPosition>1134</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1554</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1118-1134</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TVYDPLQPELDSFKEEL</LinearSequence>
                                        <StartingPosition>1118</StartingPosition>
                                        <EndingPosition>1134</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1553</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1118-1134</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TVYDPLQPELDSFKEEL</LinearSequence>
                                        <StartingPosition>1118</StartingPosition>
                                        <EndingPosition>1134</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1552</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>4.8</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1118-1134</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TVYDPLQPELDSFKEEL</LinearSequence>
                                        <StartingPosition>1118</StartingPosition>
                                        <EndingPosition>1134</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P159</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PELDSFKEELDKYFKNH</LinearSequence>
                        <StartingPosition>1125</StartingPosition>
                        <EndingPosition>1141</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>47341</EpitopeId>
                <ReferenceStartingPosition>1125</ReferenceStartingPosition>
                <ReferenceEndingPosition>1141</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1556</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1125-1141</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PELDSFKEELDKYFKNH</LinearSequence>
                                        <StartingPosition>1125</StartingPosition>
                                        <EndingPosition>1141</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1557</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1125-1141</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PELDSFKEELDKYFKNH</LinearSequence>
                                        <StartingPosition>1125</StartingPosition>
                                        <EndingPosition>1141</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1555</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1125-1141</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PELDSFKEELDKYFKNH</LinearSequence>
                                        <StartingPosition>1125</StartingPosition>
                                        <EndingPosition>1141</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P160</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EELDKYFKNHTSPDVDL</LinearSequence>
                        <StartingPosition>1132</StartingPosition>
                        <EndingPosition>1148</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>11740</EpitopeId>
                <ReferenceStartingPosition>1132</ReferenceStartingPosition>
                <ReferenceEndingPosition>1148</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1558</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1132-1148</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EELDKYFKNHTSPDVDL</LinearSequence>
                                        <StartingPosition>1132</StartingPosition>
                                        <EndingPosition>1148</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1560</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1132-1148</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EELDKYFKNHTSPDVDL</LinearSequence>
                                        <StartingPosition>1132</StartingPosition>
                                        <EndingPosition>1148</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1559</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1132-1148</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EELDKYFKNHTSPDVDL</LinearSequence>
                                        <StartingPosition>1132</StartingPosition>
                                        <EndingPosition>1148</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P161</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KNHTSPDVDLGDISGIN</LinearSequence>
                        <StartingPosition>1139</StartingPosition>
                        <EndingPosition>1155</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>32508</EpitopeId>
                <ReferenceStartingPosition>1139</ReferenceStartingPosition>
                <ReferenceEndingPosition>1155</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1561</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1139-1155</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KNHTSPDVDLGDISGIN</LinearSequence>
                                        <StartingPosition>1139</StartingPosition>
                                        <EndingPosition>1155</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1562</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1139-1155</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KNHTSPDVDLGDISGIN</LinearSequence>
                                        <StartingPosition>1139</StartingPosition>
                                        <EndingPosition>1155</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1563</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1139-1155</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KNHTSPDVDLGDISGIN</LinearSequence>
                                        <StartingPosition>1139</StartingPosition>
                                        <EndingPosition>1155</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P162</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DLGDISGINASVVNIQK</LinearSequence>
                        <StartingPosition>1147</StartingPosition>
                        <EndingPosition>1163</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>9094</EpitopeId>
                <ReferenceStartingPosition>1147</ReferenceStartingPosition>
                <ReferenceEndingPosition>1163</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1565</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1147-1163</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLGDISGINASVVNIQK</LinearSequence>
                                        <StartingPosition>1147</StartingPosition>
                                        <EndingPosition>1163</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1566</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1147-1163</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLGDISGINASVVNIQK</LinearSequence>
                                        <StartingPosition>1147</StartingPosition>
                                        <EndingPosition>1163</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1564</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1147-1163</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLGDISGINASVVNIQK</LinearSequence>
                                        <StartingPosition>1147</StartingPosition>
                                        <EndingPosition>1163</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P163</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NASVVNIQKEIDRLNEV</LinearSequence>
                        <StartingPosition>1155</StartingPosition>
                        <EndingPosition>1171</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>43316</EpitopeId>
                <ReferenceStartingPosition>1155</ReferenceStartingPosition>
                <ReferenceEndingPosition>1171</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1570</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1155-1171</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NASVVNIQKEIDRLNEV</LinearSequence>
                                        <StartingPosition>1155</StartingPosition>
                                        <EndingPosition>1171</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1569</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1155-1171</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NASVVNIQKEIDRLNEV</LinearSequence>
                                        <StartingPosition>1155</StartingPosition>
                                        <EndingPosition>1171</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1568</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1155-1171</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NASVVNIQKEIDRLNEV</LinearSequence>
                                        <StartingPosition>1155</StartingPosition>
                                        <EndingPosition>1171</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P164</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KEIDRLNEVAKNLNESL</LinearSequence>
                        <StartingPosition>1163</StartingPosition>
                        <EndingPosition>1179</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>30435</EpitopeId>
                <ReferenceStartingPosition>1163</ReferenceStartingPosition>
                <ReferenceEndingPosition>1179</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1573</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1163-1179</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KEIDRLNEVAKNLNESL</LinearSequence>
                                        <StartingPosition>1163</StartingPosition>
                                        <EndingPosition>1179</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1572</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1163-1179</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KEIDRLNEVAKNLNESL</LinearSequence>
                                        <StartingPosition>1163</StartingPosition>
                                        <EndingPosition>1179</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1571</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1163-1179</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KEIDRLNEVAKNLNESL</LinearSequence>
                                        <StartingPosition>1163</StartingPosition>
                                        <EndingPosition>1179</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P165</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EVAKNLNESLIDLQELG</LinearSequence>
                        <StartingPosition>1170</StartingPosition>
                        <EndingPosition>1186</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>14626</EpitopeId>
                <ReferenceStartingPosition>1170</ReferenceStartingPosition>
                <ReferenceEndingPosition>1186</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1575</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1170-1186</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EVAKNLNESLIDLQELG</LinearSequence>
                                        <StartingPosition>1170</StartingPosition>
                                        <EndingPosition>1186</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1576</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1170-1186</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EVAKNLNESLIDLQELG</LinearSequence>
                                        <StartingPosition>1170</StartingPosition>
                                        <EndingPosition>1186</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1574</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1170-1186</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EVAKNLNESLIDLQELG</LinearSequence>
                                        <StartingPosition>1170</StartingPosition>
                                        <EndingPosition>1186</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P166</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SLIDLQELGKYEQYIKW</LinearSequence>
                        <StartingPosition>1178</StartingPosition>
                        <EndingPosition>1194</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>59162</EpitopeId>
                <ReferenceStartingPosition>1178</ReferenceStartingPosition>
                <ReferenceEndingPosition>1194</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1577</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1178-1194</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLIDLQELGKYEQYIKW</LinearSequence>
                                        <StartingPosition>1178</StartingPosition>
                                        <EndingPosition>1194</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1579</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1178-1194</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLIDLQELGKYEQYIKW</LinearSequence>
                                        <StartingPosition>1178</StartingPosition>
                                        <EndingPosition>1194</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1578</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1178-1194</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLIDLQELGKYEQYIKW</LinearSequence>
                                        <StartingPosition>1178</StartingPosition>
                                        <EndingPosition>1194</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P167</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GKYEQYIKWPWYVWLGF</LinearSequence>
                        <StartingPosition>1186</StartingPosition>
                        <EndingPosition>1202</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>20730</EpitopeId>
                <ReferenceStartingPosition>1186</ReferenceStartingPosition>
                <ReferenceEndingPosition>1202</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1581</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1186-1202</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GKYEQYIKWPWYVWLGF</LinearSequence>
                                        <StartingPosition>1186</StartingPosition>
                                        <EndingPosition>1202</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1582</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1186-1202</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GKYEQYIKWPWYVWLGF</LinearSequence>
                                        <StartingPosition>1186</StartingPosition>
                                        <EndingPosition>1202</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1580</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1186-1202</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GKYEQYIKWPWYVWLGF</LinearSequence>
                                        <StartingPosition>1186</StartingPosition>
                                        <EndingPosition>1202</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P168</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PWYVWLGFIAGLIAIVM</LinearSequence>
                        <StartingPosition>1195</StartingPosition>
                        <EndingPosition>1211</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>50058</EpitopeId>
                <ReferenceStartingPosition>1195</ReferenceStartingPosition>
                <ReferenceEndingPosition>1211</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1584</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1195-1211</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PWYVWLGFIAGLIAIVM</LinearSequence>
                                        <StartingPosition>1195</StartingPosition>
                                        <EndingPosition>1211</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1585</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1195-1211</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PWYVWLGFIAGLIAIVM</LinearSequence>
                                        <StartingPosition>1195</StartingPosition>
                                        <EndingPosition>1211</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1583</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>9.5</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1195-1211</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PWYVWLGFIAGLIAIVM</LinearSequence>
                                        <StartingPosition>1195</StartingPosition>
                                        <EndingPosition>1211</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P169</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IAGLIAIVMVTILLCCM</LinearSequence>
                        <StartingPosition>1203</StartingPosition>
                        <EndingPosition>1219</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>25293</EpitopeId>
                <ReferenceStartingPosition>1203</ReferenceStartingPosition>
                <ReferenceEndingPosition>1219</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1586</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1203-1219</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAGLIAIVMVTILLCCM</LinearSequence>
                                        <StartingPosition>1203</StartingPosition>
                                        <EndingPosition>1219</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1588</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1203-1219</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAGLIAIVMVTILLCCM</LinearSequence>
                                        <StartingPosition>1203</StartingPosition>
                                        <EndingPosition>1219</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1587</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1203-1219</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IAGLIAIVMVTILLCCM</LinearSequence>
                                        <StartingPosition>1203</StartingPosition>
                                        <EndingPosition>1219</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P170</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MVTILLCCMTSCCSCLK</LinearSequence>
                        <StartingPosition>1211</StartingPosition>
                        <EndingPosition>1227</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>42999</EpitopeId>
                <ReferenceStartingPosition>1211</ReferenceStartingPosition>
                <ReferenceEndingPosition>1227</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1590</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1211-1227</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MVTILLCCMTSCCSCLK</LinearSequence>
                                        <StartingPosition>1211</StartingPosition>
                                        <EndingPosition>1227</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1589</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>19</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1211-1227</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MVTILLCCMTSCCSCLK</LinearSequence>
                                        <StartingPosition>1211</StartingPosition>
                                        <EndingPosition>1227</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1591</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1211-1227</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MVTILLCCMTSCCSCLK</LinearSequence>
                                        <StartingPosition>1211</StartingPosition>
                                        <EndingPosition>1227</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P171</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CMTSCCSCLKGACSCGS</LinearSequence>
                        <StartingPosition>1218</StartingPosition>
                        <EndingPosition>1234</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>6669</EpitopeId>
                <ReferenceStartingPosition>1218</ReferenceStartingPosition>
                <ReferenceEndingPosition>1234</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1594</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1218-1234</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CMTSCCSCLKGACSCGS</LinearSequence>
                                        <StartingPosition>1218</StartingPosition>
                                        <EndingPosition>1234</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1592</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1218-1234</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CMTSCCSCLKGACSCGS</LinearSequence>
                                        <StartingPosition>1218</StartingPosition>
                                        <EndingPosition>1234</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1593</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1218-1234</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CMTSCCSCLKGACSCGS</LinearSequence>
                                        <StartingPosition>1218</StartingPosition>
                                        <EndingPosition>1234</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P172</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LKGACSCGSCCKFDEDD</LinearSequence>
                        <StartingPosition>1226</StartingPosition>
                        <EndingPosition>1242</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>36856</EpitopeId>
                <ReferenceStartingPosition>1226</ReferenceStartingPosition>
                <ReferenceEndingPosition>1242</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1596</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1226-1242</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKGACSCGSCCKFDEDD</LinearSequence>
                                        <StartingPosition>1226</StartingPosition>
                                        <EndingPosition>1242</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1595</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>14.3</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1226-1242</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKGACSCGSCCKFDEDD</LinearSequence>
                                        <StartingPosition>1226</StartingPosition>
                                        <EndingPosition>1242</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1597</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1226-1242</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKGACSCGSCCKFDEDD</LinearSequence>
                                        <StartingPosition>1226</StartingPosition>
                                        <EndingPosition>1242</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>P173</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DDSEPVLKGVKLHYT</LinearSequence>
                        <StartingPosition>1241</StartingPosition>
                        <EndingPosition>1255</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>NP_828851.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>227984</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>7868</EpitopeId>
                <ReferenceStartingPosition>1241</ReferenceStartingPosition>
                <ReferenceEndingPosition>1255</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was cited in Li et. al. Nature 426 (6965), 450-454 (2003) [PMID:14647384].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1599</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 10 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized intradermally with 10 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from mice immunized with inactivated SARS-CoV was performed. Reactivity of the mouse antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1241-1255</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DDSEPVLKGVKLHYT</LinearSequence>
                                        <StartingPosition>1241</StartingPosition>
                                        <EndingPosition>1255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1598</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>21-51 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>42</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>7.1</ResponseFrequency>
                            <AssayComments>The number of positive responders is approximate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1241-1255</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DDSEPVLKGVKLHYT</LinearSequence>
                                        <StartingPosition>1241</StartingPosition>
                                        <EndingPosition>1255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1600</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>228407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Inactivated SARS</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intradermal</Route>
                                <DoseSchedule>3 doses of 30 µg, administered at intervals of 2 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>NZW rabbits were immunized intradermally with 30 ug of purified viral particles (SARS coronavirus strain BJ01) inactivated by beta-propiolactone as immunogen in the presence of CFA, and boosted with freshly prepared emulsion of the immunogen and IFA at 2-wk intervals. Antisera were collected 5 days after the third boost immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Pepscan analysis against antisera from rabbits immunized with inactivated SARS-CoV was performed. Reactivity of the rabbit antisera at 1/100 dilution with peptides overlapping the entire sequence of the S protein was measured by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>1241-1255</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DDSEPVLKGVKLHYT</LinearSequence>
                                        <StartingPosition>1241</StartingPosition>
                                        <EndingPosition>1255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>NP_828851.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>227984</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

